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ABSTRACT
Campylobacteriosis is the most common cause of human bacterial gastroenteritis in the 
developed world. Campylobacter spp. are known to colonize a wide range of land and sea 
mammals, reptiles and birds. Campylobacteriosis is also a zoonosis, with the most important 
reservoir considered to be chicken, but Campylobacter spp. are also abundantly found in other 
domestic animals. In particular, Campylobacter coli and C. upsaliensis are common colonizers of 
pigs and dogs, respectively.
Th e most oft en isolated causative agent from diseased humans is C. jejuni, but also C. 
coli and C. upsaliensis are known to cause disease, with C. coli estimated to cause 5-10% of the 
human campylobacteriosis cases. Th e disease is usually self-limiting but antimicrobial treatment 
is warranted in severe cases, with macrolides and fl uoroquinolones being the fi rst and second 
options, respectively. Intravenous aminoglycosides are indicated in Campylobacter bacteraemia.
High rates of fl uoroquinolone-resistant Campylobacter spp. have emerged in many parts of 
the world. Also, in several studies, high proportions of streptomycin (STR)-resistant C. coli or C. 
upsaliensis, have been found. However, despite recent advances in molecular characterization of 
the resistance mechanisms, complete understanding of these mechanisms for certain antibiotics 
remains lacking. Particularly, the mechanisms of STR resistance have been only partially 
characterized in C. jejuni and C. coli and completely ignored in C. upsaliensis. 
Th e primary aim of this thesis was to investigate the molecular mechanisms of STR resistance 
in porcine C. coli and canine C. upsaliensis isolates. We were able to associate high level of STR 
resistance (MIC>1024 mg/l) in porcine C. coli to mutations in the rpsL gene, which encodes 
ribosomal protein S12. In C. upsaliensis, a mutation in rpsL was also noted in all the intermediate- 
and high-level STR-resistant isolates. Even though STR resistance conferring mutations in rpsL 
codons 43 and 88 have been well documented in Escherichia coli and Mycobacterium tuberculosis, 
they were fi rst time described in Campylobacter species in the present study. 
In addition to rpsL mutations, also other mechanisms were explored to explain the 
diff erent levels of STR resistance observed in both C. coli and C. upsaliensis. Using genomics 
and insertional mutagenesis, a novel STR resistance-conferring gene (ant-like gene A) was 
identifi ed in the intermediately STR-resistant (MIC 128-512 mg/l) C. coli isolates. Th is ant-like 
gene A is located in a genomic region corresponding to the previously described hypervariable 
region 14 in C. jejuni, and we showed that it was naturally transformable to a STR-susceptible 
C. coli recipient. Th is gene is homologous, albeit at a low level, to other previously described 
aminoglycoside 6-adenylyltransferase encoding genes, and does not appear to originate from 
Gram-positive bacterial species. We hypothesize that the ant-like gene A could have evolved 
from a proto-resistance element originally having a diff erent function in Campylobacter spp., as 
we did not fi nd evidence of a recent jump of this gene to Campylobacter species.
All highly STR-resistant C. upsaliensis isolates had, in addition to the rpsL mutation, 
signifi cant truncation of rsmG, encoding a conserved methyltransferase responsible for 
methylation of the STR binding site in the 500 region of 16S rRNA. Functional deletion of rsmG 
together with changes in the rpsL have been associated with a high-level STR-resistant phenotype 
in other bacterial species, such as M. tuberculosis, Bacillus subtilis and E. coli, but, before our 
studies, have not been described in Campylobacter species. Altogether these results provided a 
signifi cant advance in understanding the mechanisms of STR resistance in Campylobacter spp. 
and will aid in predicting the phenotypic resistance from genome data.
Fluoroquinolone resistance-associated mutations in the DNA gyrase-encoding gene gyrA 
were characterized in C. coli from pigs treated with danofl oxacin (DANO) and in canine C. 
upsaliensis. Th e commonly described C257T mutation was found in both species. In C. coli 
this leads to the amino acid change T86I in DNA gyrase and high levels of ciprofl oxacin (CIP) 
resistance, while in C. upsaliensis the predicted amino acid change is T86M and only slight 
increases in CIP MICs but high levels of nalidixic acid resistance were detected. Th erefore, DANO 
does not seem to induce novel mutations in the QRDR region of C. coli in vivo.  On the other 
hand, the same mutation appears not to be suffi  cient to cause a high level of fl uoroquinolone 
resistance in C. upsaliensis. 
Macrolide resistance-associated mutations in the 23S rRNA and in the ribosomal proteins 
L4 and L22 encoding genes were studied in erythromycin (ERY) –susceptible and intermediately 
and highly resistant C. coli. All highly ERY-resistant isolates were found to have the well-
characterized A2122G mutation in 23S rRNA, while no resistance-associated mutations were 
detected in L4 and L22, indicating that the observed intermediate ERY resistance is due to other 
mechanisms such as the CmeABC effl  ux pump.
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1  INTRODUCTION
Campylobacteriosis is the most commonly reported bacterial zoonosis in the European Union 
(1). Th e predominant species isolated from human infections is Campylobacter jejuni, followed 
by C. coli, but also other Campylobacter spp. have been associated with human disease, including 
C. upsaliensis (2-6). While most human infections are self-limiting, antimicrobial treatment is 
warranted in severe cases or for immunocompromised patients, preferably using the macrolide 
or fl uoroquinolone antimicrobials with aminoglycosides indicated for septicaemia (7). 
Humans have been estimated to produce between 100  000 and 200  000 tonnes of 
antimicrobials annually, and increasing resistance rates to these agents have been observed in 
many human pathogens, including C. jejuni and C. coli (8). Th e World Health Organization 
(WHO) has warned that, unless radical measures are undertaken, we might be soon entering a 
post-antibiotic era (9). Resistance to antimicrobial agents has traditionally been considered to 
incur a fi tness cost in bacteria, but nowadays there is mounting evidence that this might not be 
true in many cases due to, for example, compensatory mutations (10, 11). 
Th e large-scale use of antimicrobials in agriculture has led to the emergence of resistant 
strains, and alarmingly high rates of resistance in C. jejuni and C. coli to certain antimicrobials, 
such as fl uoroquinolones, have been reported in many countries, recently also against 
aminoglycosides in the United States and China (12-14). Also, high rates of STR-resistant 
Campylobacter have been detected in several studies (15-19). Although STR and other 
aminoglycosides are only infrequently used in clinical settings nowadays due to their oto- and 
nephrotoxic side eff ects, the detection of ever-increasing numbers of resistant bacteria has 
revived clinical interest in this group of antimicrobials (20-22).
Th e only reported resistance mechanisms to aminoglycosides in Campylobacter spp. have 
been the presence of genes encoding aminoglycoside-modifying enzymes (AMEs) (14, 23-25). 
Th ese genes are oft en found as part of resistance plasmids or transposons containing also 
virulence or other resistance-associated genes and thought to have spread to Campylobacter spp. 
through horizontal transfer mainly from Gram-positive bacterial species (24, 26). Streptomycin 
resistance has oft en been detected in multi-resistant Campylobacter strains, indicating a common 
spread of resistance determinants. Further, we observed a statistically signifi cant increase in the 
isolation frequency of STR-resistant C. coli from pigs treated with tylosin (27). 
C. upsaliensis is commonly isolated from dog faeces and has also been reported to 
cause disease in humans, oft en associated with some underlying predisposing factor such as 
immunosuppression (3-6). Since dogs oft en are in close contact with humans, the occurrence 
of antimicrobial resistance of this canine-associated Campylobacter species is important to be 
assessed. In some studies, a high proportion of STR-resistant C. upsaliensis has been detected, 
but the resistance mechanisms have not been examined (5, 28). In addition, low rates of 
quinolone resistance have been reported, but also these mechanisms remain uncharacterized in 
C. upsaliensis (28-30).
Th e main aim of this thesis was to elucidate the mechanisms of high and intermediate-
level STR resistance in two Campylobacter spp., C. coli and C. upsaliensis. Further, macrolide 
and quinolone resistance associated mutations were studied in porcine C. coli and antimicrobial 
susceptibility patterns and quinolone resistance associated mutations were studied in C. 
upsaliensis originating from a set of Finnish dogs.
Introduction
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2  REVIEW OF THE LITERATURE
2.1  Historical highlights of Campylobacter
In 1886, Th eodor Escherich reported spiral bacteria in the faeces and colon of dead infants who 
had had diarrhoea (‘cholera infantum’) but his fi ndings were only recognized 100 years later 
in 1986 by Manfred Kist and referred to be actually diarrhoea associated with Campylobacter 
(reviewed in (31)). A vibrio resembling bacterium or spirillum was also reported from aborted 
sheep foetuses in the early 1900s by two veterinarians, McFadyean and Stockman (31) and from 
foetuses of bovines with infectious abortions by Smith and Taylor, who called the bacteria Vibrio 
fetus in 1919 (31). In addition, an agent termed V. coli was isolated from pigs with dysentery (32).
Th e fi rst well-documented human Campylobacter infections were described in 1938 
in association with a milk-borne outbreak and involved 355 inmates of two adjacent state 
institutions in Illinois, USA (33). In 1947, Vinzent et al. reported having isolated V. fetus from the 
blood of three pregnant women, two of which aborted (31, 34). In 1963, the causative agent was 
named Campylobacter, meaning curved rod in Greek with the type species of the genus being C. 
fetus (35).
However, Campylobacter spp. as infectious agents were fi rst isolated from diarrhoeic human 
faeces only in 1968 with a special fi ltration technique and plating of the fi ltrate on selective agar 
plates containing antimicrobials (36). In the late 1970s, Skirrow isolated C. coli and C. jejuni 
from the faeces of diarrhoeic individuals also using growth medium containing antimicrobials 
as selective agents. He found evidence that Campylobacter is a common cause of acute enteritis 
in humans and suggested that poultry might be the primary source of the infection (37). His 
fi ndings started a new era in the history of zoonotic Campylobacter spp.
2.2  The genus Campylobacter 
Th e genera Campylobacter and Arcobacter form the family Campylobacteraeceae belonging to the 
order Campylobacterales, which in turn is a member of the class Epsilonproteobacteria together 
with, for example, the genera Wollinella and Helicobacter. At present, the Campylobacter genus 
comprises 26 validated species (Table 1) (http://www.bacterio.net/campylobacter.html, accessed 
10.12.2015, (38)). Campylobacter spp. are Gram-negative, motile, fl agellated, curved or spiral 
rods. Most of the species require microaerobic atmosphere for growth, while some require a 
hydrogen-enriched atmosphere.  Most Campylobacter spp. grow in the temperature range of 
30-37 ºC, but the thermophilic species (e.g. C. jejuni, C. coli, C. upsaliensis and C. lari) are able to 
grow at higher temperatures (up to 42ºC) (39). Campylobacter spp. are generally very vulnerable 
to many environmental stresses, e.g. disinfectants, drying or UV radiation (3, 40), but they can 
survive certain stressful conditions, such as cold water, for long periods (3, 41, 42). 
Review of the Literature
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Table 1. Campylobacter species, the most important known hosts and reservoirs and pathogenicity to 
humans.1
Species Most important reservoir(s) and hosts Pathogenicity to humans
C. avium poultry unknown
C. canadiensis wild birds (Grus americana=whooping crane) unknown
C. coli pigs, other domestic animals diarrhoea, septicaemia, abortion
C. conscisus humans periodontal disease
C. corcagiensis Macaque (Macaca silenus) unknown
C. cuniculorum rabbits unknown
C. curvus humans gingivitis, periodontitis, periodontosis
C. fetus cattle, sheep septicaemia, abortion
C. gracilis humans periodontal disease
C. helveticus cats, dogs unknown
C. hominis humans unknown
C. hyointestinalis pigs, cattle, deer, human gastroenteritis
C. iguaniorum reptiles unknown
C. insulaenigrae marine mammals unknown
C. jejuni poultry, other domestic animals, wild birds, humans
gastroenteritis, septicaemia, 
abortion
C. lanienae humans, pigs, bovine unknown
C. lari wild birds (seagulls), other animals, water, shellfi sh gastroenteritis, septicaemia
C. mucosalis pigs unknown
C. peloridis humans, shellfi sh unknown
C. rectus humans periodontal disease, abscesses, appendicitis
C. showae humans periodontal disease
C. sputorum humans, cattle, sheep, pigs abscesses, gastroenteritis
C. subantarcticus birds unknown
C. upsaliensis dogs, cats, humans gastroenteritis, septicaemia, abortion
C. ureolyticus humans putative gastrointestinal pathogen
C. volucris wild birds (Larus ridibundus = black-headed gull) unknown
1http://www.bacterio.net/campylobacter.html (38)
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2.3  Human Campylobacter infec? ons and their reservoirs
Several Campylobacter species are commensal bacteria in their natural hosts, but able to cause 
disease in other species such as gastroenteritis and septicaemia in humans and abortion in 
bovine and sheep (39). Campylobacteriosis is the most commonly reported bacterial zoonosis in 
the European Union (1), and the incidence of campylobacteriosis seems to have risen during the 
last ten years at least in countries from which consistent monitoring data are available (43). Th e 
most important human pathogen of the genus is C. jejuni, which has been estimated to account 
for up to 90% of the human infections, followed by C. coli, which causes approximately 5-10% 
(or according to some studies up to 25%) of the campylobacteriosis cases (43-45). However, 
discrepant reports also exist with up to two-thirds of the Campylobacter isolated from human 
diarrhoeic stools being species other than C. jejuni (3, 43) and several other Campylobacter 
species have been recognized as human pathogens, including C. upsaliensis (3-6).
Enteritis caused by C. jejuni or C. coli presents as an acute infl ammatory terminal ileitis, 
cecitis and mesenteric adenitis (2). All age groups can be aff ected, but there is some evidence that 
the prevalence is higher in small children and young adults (43). In addition, other Campylobacter 
spp. can cause human gastroenteritis that may be milder and oft en go unrecognized due to 
the lack of appropriate cultivating techniques required by some of the species (43). Human 
campylobacteriosis is commonly accompanied by abdominal pain, diarrhoea and fever. Th e 
disease is usually self-limiting and no antimicrobials are needed (2). However, antimicrobial 
treatment is warranted in severe or prolonged infections and in immunocompromised patients, 
with macrolides and fl uoroquinolones being the fi rst and second treatment choices, respectively 
(2, 43). Intravenous aminoglycosides have been indicated as a fi rst-line treatment in serious 
systemic Campylobacter infections and bacteraemia (7). Several post-infectious diseases have 
been associated with campylobacteriosis, including Guillan-Barrè syndrome (GBS) and reactive 
arthritis, among others, but there are also studies fi nding association between campylobacter 
infection and several other conditions, even with the increasingly common celiac disease (46).
Campylobacter spp. are widely spread in the animal kingdom, and hosts include an extensive 
range of land and sea mammals, reptiles and birds (39). Poultry and wild birds are among the 
main reservoirs for C. jejuni and C. coli  (47), and eating or handling raw or uncooked chicken 
meat has been considered to be the most important source of human campylobacteriosis (41, 
48). Pigs have a higher prevalence of C. coli than C. jejuni (27, 49, 50), and C. upsaliensis is the 
major Campylobacter spp. recovered from dogs (51, 52). 
2.4  Campylobacter genome
Th e Campylobacter genome consist of a circular chromosome of approximately 1.6-1.7 Mb in size 
and containing about 1500-1700 coding sequences (29, 53, 54). In a study analyzing genomes of 
42 C. coli and 43 C. jejuni strains, the average C. coli genome size was found to be larger than that 
of C. jejuni (1732 vs 1609 orthologues) and also the core genome of C. coli was bigger, but the 
proportion of core to accessory genes (ca. 83%) was similar between the species (55).
Plasmids and integrated elements are part of the accessory genome and also found in 
Campylobacter spp. (24). Th ey are known to spread through horizontal transfer and can contain 
also antimicrobial resistance or virulence-associated genes. Further, also hypervariable genomic 
regions are part of the accessory genome, and in C. jejuni several of these regions (also known as 
regions of divergence or plasticity) have been described with variable genomic content consisting 
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of, for instance, genes encoding lipooligosaccharides (LOSs), motility, restriction-modifi cation 
systems and metabolism (56, 57). Th e variation in these regions results from both gene sequence 
divergence and the presence or absence of specifi c genes (58, 59). Th e putative hypervariable 
regions in other Campylobacter spp. have not been extensively studied.
2.5  An? microbial agents 
Antimicrobial agents are substances that either inhibit the growth of (microbistatic eff ect) or kill 
(microbicidal eff ect) susceptible micro-organisms.   In the broad sense, the term also includes 
antiseptics and disinfectants together with antimicrobial drugs. Antimicrobial drugs can be 
further divided into antibacterial, antiviral and antifungal substances. While the term antibiotic 
was originally used to refer only to the antibacterial agents originating from living organisms, 
such as aminoglycoside-producing Actinomycetes, it is now used in common language also for 
semi-synthetic and synthetic antimicrobial drugs. Th e term antimicrobial or antimicrobial drug 
will be used in this thesis to indicate antibacterial drugs and antibiotics. 
Antimicrobial drugs have several mechanisms of action against bacteria, the main ones 
being inhibition of synthesis of the bacterial cell wall, proteins or nucleic acids and damage to 
the bacterial cell membrane. Th ey are divided into classes based on their structure and mode of 
action. Th e main classes of interest are shown in Table 2. 
Table 2. Main antimicrobial groups of clinical interest, their mechanisms of action and their use in 
Finland.
Class Main mechanism of action Example drugs
Consumption
Human 
med1
Vet 
med2
Beta-lactams Bactericidal, inhibition of cell wall 
synthesis
Penicillins, 
cephalosporins
10.18 9763
Tetracyclines Bacteriostatic, protein synthesis 
inhibition at 50S ribosomal subunit
Tetracycline, 
doxycycline
4.52 2389
Sulphonamides, 
diaminopyrimidins
Bacteriostatic/bactericidal, folic acid 
synthesis inhibition
Sulfamethoxazole, 
trimethoprim
1.32 3129
Macrolides Bacteriostatic, protein synthesis 
inhibition at 50S ribosomal subunit
Erythromycin, 
tylosin
1.23 456
Quinolones Bactericidal, inhibition of DNA 
gyrase
Ciprofl oxacin, 
danofl oxacin
1.13 105
Aminoglycosides Bactericidal, protein synthesis 
inhibition/aberrant protein 
synthesis at 30S ribosomal subunit
Streptomycin, 
gentamicin
0.02 103
1DDD, Defi ned Daily Dose/1000 inhabitants/day in 2014 (Finnish Statistics on Medicines 2014, www.
kela.fi )
2kg of active substance in 2013 (Lääketukuista myydyt, eläimille tarkoitetut mikrobilääkkeet 2001-
2013, www.fi mea.fi )
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2.5.1  Aminoglycosides
Th e aminoglycoside group of antimicrobials (AGAs) was one of the fi rst antimicrobial classes 
introduced for clinical use in the 1940s. Th is class consists of several compounds belonging to a 
number of groups based on their core structure, but all share common structural components, 
amino-modifi ed sugars (glycosides) connected to an aminocyclitol nucleus. Th e most common 
AGAs contain 2-deoxystreptamine as a core structure (20). Th ey are natural or semisynthetic 
products of bacteria such as Streptomyces spp. and Micromonospora spp.
Aminoglycosides are positively charged, basic, highly soluble in water and relatively soluble 
in lipids (60) and contain several free hydroxyl groups and a minimum of two amino groups by 
which they bind with the 30S ribosomal structures (20). Th ey are chemically stable (61), and 
oxygen and ATP are required for the transfer of aminoglycosides into the bacterial cell (60). Th e 
majority of aminoglycosides are bactericidal, inhibiting protein synthesis by aff ecting ribosomal 
translational accuracy, translocation or proofreading. Th ey have distinct ribosomal target sites 
within the 30S subunit, and even those sharing the same core structure may have distinct eff ects 
on the ribosome (62). For example, spectinomycin inhibits translocation of peptidyl-tRNA 
between diff erent sites of 16S rRNA, while streptomycin makes the bacterial ribosome more 
prone to errors by stabilizing the error-prone state (see below) (63).
Aminoglycosides have been widely used over decades and have several indications in human 
infections including serious Campylobacter bacteraemia (7) as well as other infections caused by 
Gram-negative bacteria (60). However, their clinical applications are limited by their nephro- 
and ototoxicity (64-67). Aft er the commercial introduction of other broad-spectrum but safer 
antimicrobials in the 1970s, their use has declined worldwide (22) but in some countries, such 
as China, several aminoglycosides are still used at conventional broiler and swine farms (68). 
In Finland, the veterinary use of aminoglycosides has decreased steadily over the surveillance 
period of 2001-2013, with the sales of aminoglycosides (of active substance) decreasing from 632 
kgs in 2001 to 103 kgs in 2013 (http://www.fi mea.fi /elainlaakkeet/mikrobilaakkeiden_kulutus_
elaimilla) and consumption in food-producing animals being 0.2 mg/population correction unit 
(PCU) in 2013 (69). Th ey are also only marginally used in human medicine (Finnish Statistics 
on Medicines 2014, www.kela.fi ). Yet, with ever-increasing resistance to the newer antimicrobial 
agents, aminoglycosides are again attracting clinical interest, especially in combination therapy 
for the treatment of serious infections caused by Gram-negative bacteria or even as last-resort 
antibiotics (20-22). Several aminoglycosides, including streptomycin, are found in the WHO’s list 
of essential medicines (http://www.who.int). Gentamicin is included in the European resistance 
surveillance programme for Campylobacter (70).
2.5.1.1  Streptomycin
Streptomycin was the fi rst aminoglycoside discovered, isolated from the soil bacterium 
Streptomyces griseus in 1943 (71, 72). It was also the fi rst antimicrobial agent used successfully 
in the treatment of human tuberculosis caused by M. tuberculosis but also being eff ective against 
many Gram-negative bacteria that penicillin failed to aff ect. Its main use in humans still remains 
in the treatment of tuberculosis but it is also used to treat infections caused by the less common 
pathogens Yersinia pestis, Francicella tularensis and Brucella spp. (21, 60). Additionally, in some 
countries, it is used in plant agriculture in a spray formulation, mostly to prevent fi re blight in 
apple and pear tree orchards (73, 74). In Finland, there is still one orally administered veterinary 
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streptomycin-containing drug registered for use in piglets and calves, and indicated mainly for 
the treatment of enteric infections (75).
Figure 1. Structure of streptomycin (PubChem Compound Database).
Streptomycin is the only aminoglycoside having a guanidinylated streptamin core (20).  It binds 
to the 16S rRNA at four diff erent sites both through hydrogen bonds and salt bridges and is 
also in contact with ribosomal protein S12 encoded by the gene rpsL (63). It appears to stabilize 
the ram or error-prone state of the ribosomal 30S subunit helix 27 accuracy switch allowing the 
binding of non-cognate transfer RNAs to the ribosome and leading to aberrant protein synthesis 
(63). Th ere is also evidence that it exerts its bactericidal activity partly because it becomes caged 
in the bacterial cell. Th e mechanism proposed is through insertion of mistranslated proteins in 
the cytoplasmic membrane, which facilitates higher infl ux of the agent, and thereaft er bacterial 
proteases lyse these mistranlated proteins, trapping streptomycin and toxic protein intermediates 
inside the cell (76).
2.5.2  Quinolones
Quinolones are completely synthetic compounds originally derived from the antimalarial drug 
chloroquine. Th e fi rst quinolone, nalidixic acid, was patented in 1962 (77).  Quinolones are based 
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on a two-ring nucleus, either a naphtyridone with nitrogen at positions 1 and 8, or a quinolone 
with only one nitrogen at position 1 (77). Th ey are bactericidal in action and bind primarily to 
DNA gyrase enzyme in Gram-negative bacteria or topoisomerase IV enzyme in Gram-positive 
bacteria, the DNA supercoiling and relaxing enzymes, respectively. Th e enzymes become trapped 
on DNA, thereby blocking the progression of the DNA replication fork (78-81). 
While nalidixic acid has only low absorptivity from the gastrointestinal track and modest 
action against Gram-negative bacteria, the newer fl uorinated compounds in this class, called 
fl uoroquinolones, show marked improvements in both gastrointestinal absorption and 
spectrum of activity (77, 82, 83). Fluoroquinolones are also important in the treatment of enteric 
bacterial infections, including campylobacteriosis (84). Th e fl uoroquinolones enrofl oxacin and 
sarafl oxacin were accepted in the United States for the treatment of respiratory colibacillosis in 
chickens and turkeys in the mid 1990s but have been banned since 2005 due to the rapid increase 
of resistance among C. jejuni (85).
Nowadays, there are over 10 000 compounds derived from the bicyclic parent quinolone 
molecules (86), with several of them registered in Finland for treatment of human (ciprofl oxacin, 
levofl oxacin, moxifl oxacin, norfl oxacin, ofl oxacin) and animal (enrofl oxacin, marbofl oxacin, 
pradofl oxacin, danofl oxacin) infections (www.fi mea.fi ). Only ciprofl oxacin, danofl oxacin and 
nalidixic, which are of interest in this thesis, are discussed in more detail below.
Nalidixic acid, a quinolone, has a naphtyridone nucleus and contains an ethyl group at 
position 1 nitrogen (Fig. 2). Its main use is in the treatment of urinary tract infections in humans, 
as it concentrates in the urine (77). No quinolone antimicrobials are registered for veterinary or 
human use in Finland. Nalidixic acid is used in monitoring quinolone resistance and as an early 
indicator of emerging fl uoroquinolone-resistant bacteria in the EU Campylobacter resistance 
surveillance (70). 
Th e fl uoroquinolone ciprofl oxacin has a quinolone nucleus with a cyclopropyl group in 
position 1 nitrogen and a piperazin group in position 7 carbon (Fig. 2). It was introduced for 
clinical use in the 1980s and has a wide variety of indications in humans, including respiratory 
tract, complicated urinary tract, gastroenteric and genital infections (www.fi mea.fi ), and it is also 
included in the EU Campylobacter resistance monitoring (70). It is not used for animals.
Danofl oxacin is a veterinary fl uoroquinolone otherwise structurally similar to ciprofl oxacin 
but containing a diazabicycloheptan in position 7 carbon (Fig. 3). It is indicated for respiratory 
tract infections and enteritis in bovine and swine, with one formulation currently sold in Finland 
(75).
Figure 2. Structure of nalidixic acid (left ) and ciprofl oxacin (right) (PubChem Compound Database).
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Figure 3. Structure of danofl oxacin (PubChem Compound Database).
2.5.3  Macrolides 
Macrolides are natural or semisynthetic products of soil Streptomyces bacteria and have been 
used since the 1950s (87, 88). Th ey have a 14-, 15- or 16-membered lactone ring as a core 
structure which can contain several neutral or amino sugars (89). Th ey have been shown 
to inhibit the elongation of bacterial peptides by blocking the ribosomal exit tunnel (90, 91). 
Th ey are considered broad-spectrum and generally safe antimicrobials with only few side-
eff ects (88). Several macrolides are accepted for use in Finland, in both humans (azithromycin, 
clarithromycin, erythromycin, roxithromycin, telithromycin) and animals (spiramycin, 
tulathromycin, tylosin) (www.fi mea.fi ).
Erythromycin, a 14-membered macrolide (Fig. 4), was fi rst discovered in 1952 (92) 
and proved to be eff ective against Gram-positive pathogens, but has only modest activity 
against Gram-negative bacteria (88). It binds to the 23S rRNA macrolide binding pocket of 
the 50S subunit and this pocket is stabilized by ribosomal proteins L3, L4, L22 and L34 (88). 
Erythromycin causes the forming peptidyl-RNA to dissociate prematurely from the ribosome 
(89). Erythromycin has several clinical applications in human infectious diseases, and it is the 
fi rst-choice antimicrobial for the treatment of campylobacteriosis when antimicrobial treatment 
is needed (2). Erythromycin resistance is monitored within the Campylobacter resistance 
monitoring programme in the EU (70).
Tylosin is a 16-membered veterinary macrolide (Fig. 4) that has a similar mechanism of 
action as erythromycin. It is used mainly for the treatment of respiratory, joint and enteric 
infections in animals. In Finland, tylosin is registered for pigs, cattle, poultry, dogs and cats and 
indications in pigs include the treatment of infections such as proliferative enteropathy caused 
by Lawsonia intracellularis, swine dysentery caused by Brachyspira hyodysenteriae, Mycoplasma 
hyopneumonia infections (tylosin is an alternative treatment) and also joint infections (75). 
Moreover, tylosin has been commonly used for growth-promoting purposes in pigs worldwide 
(93). 
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Figure 4. Structure of erythromycin (left ) and tylosin (right) (PubChem Compound Database).
2.6  An? microbial consump? on and surveillance
Humans have been estimated to manufacture 100 000-200 000 tonnes of antimicrobials annually 
(8), and antimicrobials are among the most commonly purchased drugs worldwide (94). Th ese 
drugs are not used only for the treatment of human and animal infectious diseases. A large 
part of the produced antimicrobials is in fact consumed in agriculture for disease prophylaxis, 
metaphylaxis and growth promotion of food-producing animals, mainly chickens and pigs, in 
many parts of the world (95) and also in aquaculture and horticulture (8). In the EU member 
states, the use of antimicrobials for growth promotion purposes has been banned since 2006 
(EU regulation no. 1831/2003). However, in several other countries such as the United States, 
antimicrobial use for growth promotion is allowed. In the United States alone, 15 000 tonnes of 
antimicrobials (of active ingredient) were sold in 2013 for use in food-producing animals  (96), 
while, for comparison, less than 3300 tonnes were estimated to be sold for human use in 2011 
(95). In the EU (a total of 26 countries), 3400 tonnes of antimicrobials (of active ingredient) 
were sold for humans and 7982 tonnes for use in food-producing animals in 2012 (97).  Further, 
global consumption of antimicrobials for food-producing animals was estimated to be >60 000 
tonnes in 2010 and forecasted to rise to >100 000 tonnes by 2030, mainly due to the increasing 
number of food-producing animals (95).
Surveillance activity of antimicrobial consumption varies between countries and regions, 
with well-established regular surveillance programmes in, for example, Canada, the US and most 
European countries. However, in many countries, surveillance is less regular (Australia, New 
Zealand) or non-existent (most developing countries). EU member countries report veterinary 
sales fi gures to the European Medicines Agency (EMA) overseeing the European Surveillance 
of Veterinary Antimicrobial Consumption (ESVAC) and human sales to the European Centre 
for Disease Prevention and Control (ECDC), which coordinates the European Surveillance of 
Antimicrobial Consumption network (ESAC-net). 
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In Finland, the Finnish Medicines Agency (Fimea) collects data on antimicrobial sales for 
animals. Total sales of veterinary antimicrobials in Finland in 2013 were 16.3 tonnes (http://
www.fi mea.fi /elainlaakkeet/mikrobilaakkeiden_kulutus_elaimilla) and for food-producing 
animals 12.5 tonnes (cf. Sweden 10 tonnes, France 681 tonnes, Italy 1318 tonnes) (69). Corrected 
with PCU, which takes into account the size of the food animal population in each country, the 
consumption for food-producing animals in Finland was 24.3 mg/PCU, which is low relative to 
most other EU countries (Sweden 12.6 mg/PCU, France 95 mg/PCU, Italy 302 mg/PCU) (69). Th e 
most sold classes of veterinary antimicrobials in Finland were β-lactams (G-penicillin), followed 
by sulfonamide-trimethoprim and tetracyclines (Table 2). However, little or no information is 
available on the Finnish antimicrobial consumption per animal species or indication group. 
Th e low level of veterinary consumption in Finland can be accounted to several factors. 
Th ese include effi  cient eradication of many common infectious animal diseases, veterinarians 
being allowed to hand over antimicrobials to animal owners in Finland but without profi t 
(Lääkelaki 395/87) and all antimicrobial usage requiring a prescription. For example, in humans, 
the non-prescription use of antimicrobials has been estimated to range from 19% to 100% of 
total antimicrobial use in countries outside of the northern Europe and North America (94). 
Because diff erent units are used in surveillance of antimicrobial consumption (sales) for 
animals (kg of active substance) and humans (defi ned daily dose, DDD), comparison of the 
data is diffi  cult (Table 2). However, in a recent EU report, it was estimated that approximately 
47.3 tonnes of active ingredient of antimicrobials was used for humans in Finland in 2012 (as 
converted back from DDD) (97), while total veterinary sales were 16.0 tonnes (http://www.fi mea.
fi /elainlaakkeet/mikrobilaakkeiden_kulutus_elaimilla) with production animals accounting for 
12.2 tonnes (97). Th us, veterinary antimicrobials accounted for 25% of total antimicrobial sales, 
with 19% intended for food-producing animals in Finland (97). However, these numbers are 
only very rough estimates of usage, as several factors cannot be accounted for, including, off -label 
use of antimicrobials in animals and diff erences between sales fi gures and actual consumption. 
2.7  AnƟ microbial resistance monitoring and suscepƟ bility 
tesƟ ng
Antimicrobial susceptibility testing is performed both for guiding the therapy of infectious 
bacterial diseases and for epidemiological monitoring of bacterial resistance rates. According 
to Directive 2003/99/EC, all EU member states are required to provide antimicrobial resistance 
monitoring data. In Finland, antimicrobial resistance monitoring from pathogenic bacteria 
from humans is coordinated by the National Institute for Health and Welfare and the Finnish 
Study Group for Antimicrobial Susceptibility Testing (FiRe). Resistance data from zoonotic and 
indicator bacteria from animals are collected by the Finnish Food Safety Authority. Th e results 
of monitoring are published regularly in national FINRES and FINRES-Vet reports. EU-wide 
surveillance data are collected by the European Food Safety Authority (EFSA) and ECDC, which 
publish the resistance prevalence data annually.
Two diff erent criteria are used for dividing bacteria into susceptible and resistant 
populations. Th e European Committee on Antimicrobial Susceptibility Testing (EUCAST) 
defi nes clinical resistance in the context of the likelihood of therapeutic success or failure at the 
achievable antimicrobial activity at the desired body site using clinical breakpoints. On the other 
hand, for monitoring purposes, microbial resistance is defi ned by the absence or presence of 
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acquired resistance mechanisms for the tested antimicrobial, dividing bacteria into wild-type 
(WT) and non-wild-type (NWT) populations using epidemiological cut-off  (ECOFF) values 
derived from MIC (minimum inhibitory concentration) distributions of studied bacterial 
populations (www.eucast.org). Th e MIC is defi ned as the lowest antimicrobial concentration 
inhibiting all visible growth of an organism aft er overnight incubation (for certain organisms, 
including Campylobacter spp., the incubation period is extended due to slower growth) (98). For 
a given bacterial species, the clinical break-points and ECOFFs can diff er from each other.
Several phenotypic and genotypic methods exist for testing antimicrobial susceptibility. 
Commonly used phenotypic methods are agar dilution, broth macro- and microdilution, disc 
diff usion and E-test (PDM Epsilometer, AB Biodisk, Solna, Sweden). In the dilution methods, 
generally performed by cultivating bacteria on agar plates containing serial dilutions of an 
antimicrobial agent or inoculating broth in test tubes or microtitre wells containing doubling 
concentrations of antimicrobial, the antimicrobial activity is defi ned by the fi rst concentration 
with no visible growth of bacteria (MIC). In disc diff usion tests and E-test, the growth inhibition 
zone around a disc or strip containing an antimicrobial is measured. 
Genetic resistance testing methods are based on detecting a known resistance associated 
gene or mutation by PCR and sequencing or by using genomic data acquired through next-
generation sequencing (NGS) techniques. Th ese methods provide a fast and effi  cient way to 
detect antimicrobial resistance for mechanistic and epidemiological screening. 
Th e fi rst standardized phenotypic susceptibility testing method for Campylobacter spp., agar 
dilution, was only available as late as in 2004 (99). At present, EUCAST has standardized disc 
diff usion and broth microdilution methods while the Clinical and Laboratory Standards Institute 
(CLSI) recommends using the agar dilution and broth microdilution methods for C. jejuni and 
C. coli (13). At the time of writing, the document summarizing EUCAST methodology for MIC 
determination of non-fastidious and fastidious organism was under preparation (www.eucast.
org).
2.8  AnƟ microbial resistance prevalence and mechanisms
Antimicrobial resistance is a growing problem worldwide and the World Health Organization has 
expressed a concern that unless drastic actions are taken we might be entering the post-antibiotic 
era already in the 21st century. Th is means that micro-organisms will become so resistant to 
common antimicrobials that no treatment options remain and we will face a situation in which 
even a minor injury/infection can lead to death (9). While the large-scale use of antimicrobials 
by humans only began in the 20th century, antimicrobial agents, and consequently, antimicrobial 
resistance-conferring genes, are ancient and very prevalent in, for example, environmental 
bacteria (100). Th e environment has been proposed to be a rich source of resistance genes readily 
mobilized into pathogenic bacteria upon selection and a concept of an antimicrobial resistome 
has been introduced and suggested to include all known antibiotic resistance genes and their 
precursors (100). Bacteria are known to exchange DNA through transduction, transformation 
and conjugation facilitating horizontal transfer of resistance-conferring genes. In addition, while 
harboring antimicrobial resistance-conferring mutations and genes have been traditionally 
thought to incur a fi tness cost to an organism (101), there is now growing evidence of cost-free 
mutations and that several compensatory mechanisms can alleviate fi tness costs, indicating that 
even cessation of the use of antimicrobials does not necessarily eradicate resistant strains at, for 
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instance, animal production facilities (10, 11). Th is is a concern also since there is mounting 
evidence that an increase in antimicrobial consumption in animals can increase the occurrence 
of resistant bacteria in humans (9, 97).
In general, antimicrobial resistance in bacteria can be conferred by three main mechanisms: 
decreasing antimicrobial entrance into the cell usually conferred by effl  ux mechanisms or 
reduced permeability of the cell membrane, drug target alteration that prevents the binding of 
the drug and enzymatic modifi cation of antimicrobials (102). Resistance can also be divided into 
intrinsic and acquired forms. Intrinsically resistant bacterial species are naturally resistant to 
certain antimicrobials, for example, due to lack of a binding site for the drug or having a growth 
environment that does not favor the action of the antimicrobial. Campylobacter are considered 
intrinsically resistant to several antimicrobials such as polymyxin, novobiocin, cephalothin, 
cefoperazone and rifampin (103-105). Acquired resistance, on the other hand, can be conveyed 
by obtaining resistance encoding genes or mutations in bacterial genomes or increased 
action of certain effl  ux pumps. Th e main resistance mechanisms described in Campylobacter 
spp. are schematically presented in Fig. 5 and those relevant for this thesis, namely against 
aminoglycosides, quinolones and macrolides, are discussed further below.
Figure 5. Main resistance mechanisms described in Campylobacter spp. Aminogl.: aminoglycosides β: 
β-lactams, CmeABC: effl  ux pump, MOMP: major outer membrane protein, mRNA: messenger RNA, 
Tet: tetracycline,  TetO: ribosomal protection protein, 30S, 50S: bacterial ribosomal subunits. Published 
in (106).
Review of the Literature
F
Q 
Macro 
lides 
C
m
e 
A
B 
C 
β 
F
Q 
70S bacterial ribosome 
50S  
30S mRNA Amino
gl. 
Macro 
lides 
Tet 
Macro 
lides 
F
Q 
Amino
gl. 
β 
Tet 
Tet 
26
2.8.1  Resistance to aminoglycosides 
A commonly described aminoglycoside resistance mechanism in bacteria is enzymatic 
modifi cation of the drugs, and a vast number of genes encoding these modifi cation enzymes 
have been described in a vast number of bacterial species (107-109). Th e aminoglycoside-
modifying enzymes (AMEs) are divided into three groups based on their mode of action, namely 
the phosphotransferases (APH), acetyltransferases (AAC) and nucleotidyl/adenylyltransferases 
(ANT), the second forming the largest and the last the smallest group (107). Th ese enzymes 
function by phosphorylating, acetylating or adenylylating a specifi c free hydroxyl or amino 
group of the drug, thereby leading to inactivation (20). Th e AMEs form a heterologous group 
of enzymes, sometimes only sharing the ability to inactivate one or several aminoglycosides. 
Especially adenylyltransferases but also certain subgroups of phosphotransferases can share only 
low amino acid sequence identity with other members of the group (110-112).
Th ere are two diff erent nomenclature systems used for AMEs and their encoding genes, 
which further complicates the research of these enzymes and creates confusion. For example, 
in some occasions, the same name has been applied to two diff erent enzymes (113). Th e system 
used in this thesis consists of a three-letter capitalized code specifying the enzymatic action (as 
above) followed by the site of modifi cation as a number in parentheses and a Roman numeral 
indicating the resistance profi le conveyed. In this system, the encoding genes are named with the 
same characters, but in lowercase and in italics (107, 113). 
AME-encoding genes in bacteria are oft en located in transferrable genetic elements such 
as plasmids, integrons or transposons, commonly accompanied by other resistance or virulence 
genes, but they have also been found in chromosomes with no obvious indication of horizontal 
transfer mechanism. Th ese genes could have evolved primarily in antibiotic-producing, mainly 
Gram-positive, soil bacteria and spread via horizontal transfer to other species or they could have 
arisen through convergent evolution in numerous bacterial species from chromosomal genes 
encoding enzymes originally with diff erent functions and substrates (20, 108, 112, 114, 115). 
Some AMEs have been shown to have greater affi  nity for substrates other than aminoglycosides 
(116). For example, AAC(2’)-Ia, a gentamicin resistance-conferring acetyltransferase encoded 
chromosomally in Providencia stuartii, has been shown to contribute to peptidoglycan 
O-acetylation  (117). In addition to AME-encoding genes being oft en detected together with 
other resistance genes, there is at least one report of an aminoglycoside acetyltransferase that has 
acquired enzymatic activity capable of fl uoroquinolone modifi cation in E. coli (118).
Also, target binding site modifi cation can confer aminoglycoside resistance. It can be due to 
mutations in the 30S ribosomal structures such as 16S rRNA (119) or enzymatic modifi cation of 
the target site by 16S rRNA-methyltransferases (16S-RMTases), found in a number of pathogens, 
the encoding genes oft en also located in transferrable genetic elements such as plasmids (120, 
121). However, the origins of the 16S-RMTase-encoding genes in pathogenic bacteria remain 
unknown (121).
For streptomycin, the most common resistance mechanism is the enzymatic drug 
modifi cation mediated by ANT(6), ANT(3”), APH(6) and APH(3”) classes of enzymes (107). 
Also, mutations at the ribosomal target sites, mainly in the rrs gene encoding 16S rRNA (122-
124) and in rpsL encoding ribosomal protein S12, have been shown to result in streptomycin 
resistance (124-126). Mutations in 16S rRNA are clinically important merely in M. tuberculosis, 
which contains only one copy of the gene. On the contrary, mutations in the rpsL gene (in 
codons 43 and 88, C. coli numbering) have been associated with streptomycin resistance in 
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several bacterial species including E. coli, M. tuberculosis and Helicobacter pylori (122, 125, 
126). Interestingly, mutations in a conserved 7-methylguanosine methyltransferase encoding 
gene rsmG (also known as gidB), resulting in a loss of function and consequently absence of 
methylation of a specifi c streptomycin binding site in bacterial 16S rRNA have been reported to 
confer a low level of streptomycin resistance in several bacterial species (127-130). In contrast, 
methylation of the target site by 16S-RMTases has not been associated with streptomycin 
resistance (121). 
2.8.1.1  Aminoglycoside resistance in Campylobacter spp.
In recent years, increasing rates of isolation of gentamicin-resistant Campylobacter strains 
originating from humans, animals and animal products have raised concerns both in the US and 
in China (12, 14). In addition, in many studies high incidence of streptomycin resistance in C. coli 
originating from both humans and animals has been reported (15-19, 131) and a higher rate of 
streptomycin-resistant isolates has been detected in C. coli than in C. jejuni (18, 132). Especially 
among porcine C. coli, high rates (48-90%) of streptomycin-resistant strains, oft en also resistant to 
other antimicrobials, have been reported in many countries, including Canada, Japan, Denmark, 
Switzerland and Italy (15-17, 131, 133, 134). In Finland, in a study of antimicrobial resistance in 
C. jejuni originating from several domestic sources, only one isolate resistant to gentamicin was 
detected, but the streptomycin resistance rate varied from 0 to 31% between sources (135).  No 
gentamicin-resistant C. jejuni strains from broilers or C. coli from pigs were detected in 2013 in 
Finland, but 2.3% of C. coli from broilers were resistant to gentamicin and 37.4% of C. coli from 
pigs were resistant to streptomycin ((70), www.zoonoosikeskus.fi ). However, most of the STR 
resistant porcine C. coli isolates had only small increase of STR MIC (8 mg/l) and excluding these 
isolates from the resistant fraction, the proportion of STR resistant isolates was 10.7%.
Also, a high incidence of streptomycin resistance has been reported among C. upsaliensis (5, 
28) and streptomycin resistance has been proposed to be intrinsic for this species (28). Another 
study found that C. upsaliensis strain isolated from a human patient was resistant (unlike most 
other Campylobacter species studied) to nalidixic acid, oxytetracycline and novobiocin, but not 
to streptomycin or most of the β-lactam antibiotics, including an amoxicillin-clavulanic acid 
combination, commonly used for various indications in small animal practice in Finland (29). 
However, the mechanisms of streptomycin resistance in C. upsaliensis have not been characterized 
and overall data on the prevalence of antimicrobial resistance among Campylobacter spp. from 
Finnish dogs are scarce or non-existent.
Numerous complete and partial sequences of AME-encoding genes have been detected in 
C. jejuni and C. coli (Table 3) (14, 24, 25, 68, 111, 136-141) oft en located in  multidrug resistance 
plasmids (14, 24, 29, 141), chromosomally in genomic islands containing also other resistance 
or pathogenicity genes (25, 68) or as a part of integrons (140, 142). In particular, aminoglycoside 
6-adenylyltransferase encoding genes, called ant(6), aadE or aadK, have been frequently 
described as part of a resistance gene triplet aadE-sat4-aphA3 in Campylobacter spp. (14, 24, 68, 
141) and they have shared sequence similarity with those from Gram-positive bacteria (24, 25, 
68, 143). Other aminoglycoside resistance mechanisms have not been previously described in 
Campylobacter spp.
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Table 3. Aminoglycoside and streptothricin resistance genes detected in Campylobacter spp.
Gene1 Resistance 
conferred
Species Location Reference2
aac kanamycin/not 
defi ned
C. jejuni/C. coli plasmid/
chromosome
(24, 68)
aacA-AphD not defi ned C. coli chromosome (68)
aac(6’)-Ie/
aph(2”)-Ia
not defi ned C. coli not defi ned (23)
aac(6’)-Ie/
aph(2”)-If2
not defi ned C. jejuni not defi ned (23)
aacA4 tobramycin, 
gentamicin
C. jejuni not defi ned (140)
aad9 spectinomycin C. jejuni, C. coli plasmid (14, 24)
aadA non-functional C. jejuni plasmid (24)
aadE streptomycin C. jejuni, C. coli plasmid (14, 24, 68, 139, 141)
ant(6)-Ib streptomycin C. fetus subsp. fetus chromosome (25)
aph(2”)-Ib gentamicin C. jejuni not defi ned (144)
aph(2”)-Ic gentamicin C. coli not defi ned (144)
aph(2”)-Ig gentamicin C. coli not defi ned (144)
aph(2”)-Ih gentamicin C. coli, C. jejuni not defi ned (144)
aph(2”)-If(1-3) kanamycin, 
gentamicin, 
tobramycin, 
dibekacin, 
sisomicin
C. jejuni, C. coli plasmid/
not defi ned
(23, 24, 111)
aph(2”)-Ig gentamicin, 
kanamycin
C. coli plasmid (14)
aphA-3 kanamycin C. jejuni, C.coli plasmid, 
choromosome
(14, 24, 68, 137, 141, 
145)
aphA-7 kanamycin C. jejuni/C. coli plasmid/
not defi ned
(68, 146)
sat4 streptothricin C. jejuni, C.coli plasmid, 
chromosome
(14, 24, 68, 141)
1Annotation used by the authors has been applied
2Even though several studies have described genes annotated identically (e.g. aadE), their nucleotide 
sequences might diff er signifi cantly
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2.8.2  Resistance to quinolones
Common quinolone resistance mechanisms in bacteria include mutations in the quinolone 
resistance determining region (QRDR) of the GyrA subunit of DNA gyrase or the ParC of the 
topoisomerase IV. Also reduced cell permeability or increased effl  ux has been shown to contribute 
to quinolone resistance (Fig. 5) (81). Further, a plasmid-mediated quinolone resistance gene 
conferring a low level of resistance has been described in certain Gram-negative bacteria, but not 
in Campylobacter (147, 148).
Since Campylobacter spp. lack the parC and parE genes encoding the topoisomerase IV 
subunits, resistance to quinolones is  generally mediated by mutation(s) in the gyrA gene and 
by increased effl  ux by an unspecifi c CmeABC effl  ux pump (53, 149-152). Th e most commonly 
described resistance-conferring mutation in C. jejuni and C. coli is the one leading to amino 
acid substitution T86I (Th reonine86Isoleucine) in GyrA resulting in a high level of resistance. 
Other substitutions in QRDR of GyrA have also been associated with various levels of quinolone 
resistance or resistance to nalidixic acid only (150, 151, 153-156). Unlike in bacteria containing 
two targets for the quinolones, development of quinolone resistance in Campylobacter is not 
a stepwise process, but a single point mutation in the QRDR of gyrA can lead to high levels 
of resistance (156-158), indicating that these species are sensitive indicators on the use of 
fl uoroquinolones. Further, it has been suggested that fl uoroquinolone resistance does not incur 
a fi tness cost in C. jejuni, as resistant isolates have been shown to outcompete susceptible ones in 
chicken (159). 
Aft er the introduction of fl uoroquinolones in human and veterinary medicine in the 1980s, 
increasing rates of resistant Campylobacter isolates have been detected worldwide (160, 161). 
Even though the use of fl uoroquinolones in poultry production in the US was banned in 2005, 
there are reports showing that quinolone-resistant Campylobacter persists in poultry for years 
aft er usage, further complicating the eradication of resistant strains (85, 162). In countries mainly 
located in the southern and eastern parts of Europe, high resistance rates in C. coli and C. jejuni 
(>90%) have been reported in humans and animals, while the Nordic countries have generally 
had low rates of resistance (13, 70). Further, higher rates of fl uoroquinolone resistance have been 
detected among C. coli than C. jejuni in studies from several countries (13). 
In 2013, none of the investigated Finnish C. jejuni isolates from broilers were resistant to 
ciprofl oxacin, but 9.2% were resistant to nalidixic acid, and 18.3% of the C. coli from pigs were 
resistant to ciprofl oxacin (70). In 2014, the national monitoring programme found 25% of the 
studied C. jejuni from broilers to be quinolone-resistant (www.zoonoosikeskus.fi ).
2.8.3  Resistance to macrolides
Resistance to macrolides is mainly conferred by alterations in the ribosomal drug binding sites, 
either by acquisition of a methylase-encoding gene (erm) or through mutations in the host 
ribosomes, and by increased effl  ux (Fig. 5). Th e methylating genes are usually found in Gram-
positive species and they methylate specifi c macrolide binding sites of 23S rRNA, thereby 
inhibiting the binding (88). Th e resistance conferring mutations in the host ribosomes are mainly 
located in the macrolide binding sites of the 23S rRNA (163). Th e other prevalent resistance 
mechanism is increased effl  ux by an effl  ux pump that is mediated through acquisition of genes 
encoding effl  ux-proteins by Gram-positive species (164, 165) or by intrinsic non-specifi c 
transport systems, mainly found in Gram-negative species (88).
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Th e described mechanisms of macrolide resistance in Campylobacter include mutations 
in the 23S rRNA macrolide binding sites and increased effl  ux by the non-specifi c CmeABC 
effl  ux pump (29, 166-168). Campylobacter have three copies of the 23S rRNA gene and at least 
two mutated copies are needed for a resistant phenotype (166, 169). Also mutations in the 
ribosomal proteins L4 and L22 have been associated with a low level of macrolide resistance in 
Campylobacter (170, 171). Further, among Campylobacter spp., the erm gene was fi rst described 
in C. rectus (172), and it was recently found to confer a high level of macrolide resistance also in 
several C. coli isolates originating from China. In C. coli, it was found to be a part of a transferrable 
multiple drug resistance genomic island probably originating from Gram-positive bacteria (173, 
174). Macrolide resistance has been thought to incur a fi tness cost in Campylobacter (175), but 
there are no studies on the eff ect on fi tness in Campylobacter spp. aft er the acquisition of this new 
resistance determinant. 
Compared with fl uoroquinolones, macrolide resistance is not as common among C. jejuni 
from animals in EU countries, with the highest rate of 2.8% detected in Spain and no resistance 
in Finland in 2013 (70, 135). However, higher rates of macrolide-resistant C. coli than C. jejuni 
have been frequently reported (3, 70, 93, 163) with average ERY resistance of C. coli from broilers 
in 2013 being 13.7% compared with 0.4% in C. jejuni isolated from the same source in EU (70). 
Large diff erences in the prevalence of ERY-resistant C. coli from broilers were seen between 
countries, varying from 0 in several countries to 43% in Spain. Further, on average 20.7% of the 
porcine C. coli isolates were resistant to ERY in 2013 in the EU, but also varying greatly, from 
2.3% in Finland to 58.3% in Spain (70).
2.9  Whole-genome sequencing and applicaƟ ons in resistance 
research
2.9.1  Sequencing technologies, assembly and annota? on
Sanger sequencing technology was fi rst introduced in 1977 (176) and relied on incorporating 
dideoxynucleotides in four separate reactions to DNA in vitro, terminating the elongation of 
the forming nucleotide chain. Originally, these resultant DNA fragments were visualized on 
an agarose gel and the order of the nucleotides in the template DNA strand was deduced by 
the size of the fragments in four lanes (176). Improvements were subsequently made, including 
radioactive labelling of dideoxynucleotides, which enabled the use of one reaction instead 
of four, and partly automated sequencing (177). Sanger sequencing was used to generate the 
fi rst whole-genome sequence of the bacterium Haemophilus infl uenza (178) and also the fi rst 
draft  sequences of a human genome in 2001 (179). However, the laborious and costly nature of 
Sanger sequencing prevented its large-scale use for complete genomes and thus, next-generation 
sequencing (NGS) technologies (also known as deep sequencing, high throughput sequencing or 
massively parallel DNA sequencing) were developed (179).
Th e most important NGS techniques can be divided into two wide categories, those that rely 
on amplifi ed DNA libraries of the template and those that do not require amplifi cation but can 
determine the nucleotide sequence of a single DNA molecule (180). Th e sequencing equipment 
can also be divided into high-end and bench top sequencers based on the speed and number of 
bacterial genomes sequenced in one run (180, 181).
In amplifi cation-based sequencing, the template DNA is fi rst isolated in suffi  cient quantity, 
fragmented with a variety of methods in fragments of suitable length, tagged with adaptors 
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and amplifi ed on a solid surface to enable large-scale parallel sequencing (180, 182). All of 
the amplifi cation-based sequencing methods rely on sequencing by synthesis or sequencing 
by ligation principle, but vary in technical details (180, 183). For example, the Illumina Solexa 
technology (Illumina Inc., San Diego, CA, USA) is based on reversible termination of elongation 
in which terminator nucleotides with fl uorescent labels emitting at diff erent wavelengths are 
perfused across the sequencing cell and the resulting signals are imaged. Th e terminator dye is 
then enzymatically cleaved to allow insertion of the next nucleotide ((180), www.illumina.com). 
Sometimes it is challenging to discriminate the A and C signals as well as the G and T signals due 
to similar emission spectra of the fl uorophores, and base substitution is the main error type in 
this technology (182, 184). Th e Ion Torrent (Life Technologies Corporation, Grand Island, NY, 
USA) technology is based on adding only one kind of nucleotide at a time on the template, and 
the signal (a hydrogen ion) is detected when insertion occurs (180). As all of these technologies 
have weaknesses, sequence quality should always be assessed considering also the sequencing 
technology used (182, 183). 
In the newest technologies sequencing is performed on single DNA molecule templates 
without an amplifi cation step (180). In 2012, a new single DNA molecule sequencing technology 
based on feeding the template (unamplifi ed) DNA through protein nanopores was introduced, 
and a complete E. coli genome was assembled de novo (see next section) using only data generated 
by the nanopore technology in 2015 (180, 183, 185).
Th e challenge of NGS is in the handling and storing of the large amount of information 
generated. Th e sequence data, also known as reads, can vary in size from less than one hundred 
bases to several kilobases, depending on the technology used (183). Th ese reads need to be 
assembled into longer continuous DNA sequences, called contigs, and two diff erent approaches 
are used in assembly. Reads can be mapped to a known reference genome or assembly can 
be performed without a reference, also called de novo assembly (180). Th e de novo fragment 
assembly can be described as the problem of reconstructing a DNA string from its k-mers and 
diff erent mathematical approaches are used in solving it (186-188). Th ousands of assembly 
algorithms have been written and many assemblers exist, such as ABySS (Assembly By Short 
Sequences) (189), MIRA (Mimicking Intelligent Read Assembly), SPAdes (188) or Velvet (190). 
All of these are optimized for reads generated by certain sequencing technologies, performing 
reference-based or de novo assemblies or both (183).  
Aft er assembly of reads into contigs, annotation can be performed using a variety of 
programs, such as a free online tool, the RAST (Rapid Annotation using Subsystem Technology) 
server (191). Automatic annotation is usually based on putative gene detection and function 
prediction by comparison with known genes in databases (187). Th e annotation process is far 
from fl awless and may miss or wrongly annotate several hundred coding sequences (CDS), 
therefore requiring human input, also called manual curation (187).  Since most genomes in 
public databases are annotated only automatically, the putative errors need to be taken into 
account when utilizing these resources.
2.9.2  Whole-genome sequencing approach in an? microbial resistance 
research
NGS technologies provide a means of studying bacterial genomes in more detail and with higher 
resolution than ever before. In relation to antimicrobial resistance, sequence data can be utilized 
in, for example, studies of the epidemiology of resistant bacteria, as a basis for new antimicrobial 
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drug development or for surveillance of bacterial resistance rates based on well-characterized 
resistance-conferring genes and mutations, such as those in the QRDR region of gyrA in the 
case of fl uoroquinolone-resistant Campylobacter (181, 192). Resistance gene databases have been 
set up to aid the screening of WGS data and enable mining for and recognition of putative or 
existent resistance-conferring genes (193, 194).
Also, considerable interest has been directed at the characterization of new resistance 
mechanisms and genes based on whole-genome sequencing. Several new resistance-conferring 
mutations, genes and multidrug resistance islands have been uncovered using NGS in many 
bacteria, including Campylobacter (14, 23, 195).  For instance, Chen et al. (2013) (14) were able 
to fi nd several novel aminoglycoside resistance genes located in MDR plasmids in C. coli using 
NGS. In addition, WGS has revealed many cryptic or potential resistance genes, e.g. those coding 
for proteins resembling aminoglycoside-modifying enzymes, embedded in the genomes of many 
pathogens (100). Th ese cryptic genes have been called resistance precursors or proto-resistance 
elements and have been suggested to be included in to the antibiotic resistome (100, 115). 
As NGS techniques have become increasingly aff ordable and more user-friendly data 
analysis tools are being developed, it seems likely that many laborious genotyping as well as 
phenotypic antimicrobial resistance screening methods will be replaced by NGS techniques in 
the near future (196). For example, analysis of WGS data for resistance associated-genes and 
mutations was found to be a highly accurate method for predicting antimicrobial resistance 
phenotypes in C. jejuni and C. coli (144). However, these methods are unlikely to completely 
replace traditional phenotypic methods due to the fact that resistance conferred by, for instance, 
increased activity of effl  ux pumps or a completely new mechanism would not be detected by 
studying only known genetic changes. Also, in many cases, the level of resistance cannot be 
precisely predicted using only genomic data.
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3  AIMS OF THE STUDY
Th e aims of this thesis were to characterize the mechanisms of high and intermediate STR 
resistance in porcine C. coli and canine C. upsaliensis and to fi nd putative connections between 
resistance to STR and macrolides in C. coli. Further, the occurrence of antimicrobial resistance 
in Campylobacter spp. from a set of dogs was investigated, and mutations associated with 
fl uoroquinolone and macrolide resistance in C. coli and quinolone resistance in C. upsaliensis 
were studied.
Specifi c objectives were as follows:
1.  To characterize the mechanism of high-level STR resistance in C. coli and to fi nd potential 
connections between macrolide and STR resistance (I)
2.  To investigate the mechanisms, origins and natural transformation capability of 
intermediate-level STR resistance in C. coli (III)
3.  To analyse the eff ect of DANO and tylosin treatments of pigs on STR resistance in C. coli at 
farm level and to investigate the mutations associated with macrolide and fl uoroquinolone 
resistance in C. coli with special attention to DANO-induced changes in QRDR of gyrA 
(II, III)
4.  To characterize the potential STR and quinolone resistance-associated mutations in C. 
upsaliensis from dogs and to assess the occurrence of antimicrobial resistance among 
canine Campylobacter spp. (IV)
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4  MATERIALS AND METHODS
4.1  AnƟ microbial treatments and sampling scheme of 
animals
4.1.1  Pigs
In Study I, the 17 STR- and/or ERY-resistant C. coli isolates originated from 15 pigs from two pig 
farms. At farm 1, tylosin was used for weaned piglets for the treatment of proliferative enteropathy 
caused by Lawsonia intracellularis, and occasionally penicillin, sulfadiazine-trimethoprim and 
aminopenicillin were used (detailed description of medications can be found in (27)). At farm 
2, penicillin and sulfadiazine-trimethoprim were used if needed. No aminoglycoside treatments 
had been recorded from either farm at least for the past four years prior to the sampling. 
In Study II, 27 piglets from farm 3 were included and part of the animals (group A, n=12 
pigs) were treated intramuscularly (im) with DANO for three days at a dose of 3.3 mg/kg at 4-5 
days at weaning due to diarrhoea caused by E. coli and tylosin in feed at a dose of 3-6 mg/kg for 10 
days starting at 11 days aft er weaning, whereas the controls (group B=15 animals) received only 
tylosin without DANO treatment. Additionally, three piglets from both groups were treated with 
amoxicillin im before weaning. Pigs were sampled at six time points: before weaning (sampling 
I), aft er weaning (samplings II and III), aft er DANO medication of group A (samplings IV and 
V) and aft er tylosin treatment of both groups (sampling VI). Th e animals were reared in three 
pens, each containing animals from both groups.
4.1.2  Dogs
Th e 36 dogs in Study IV were Staff ordshire bull terriers originating from a total of 30 households 
located in diff erent parts of Southern Finland and aged between 1 and 12 years. Th ey were 
sampled twice, before and at the end of a feeding period lasting 4-5 months and consisting of 
either raw feed or pelleted dry feed. No systemic antimicrobial treatments were recorded from 
the sampled dogs right before or between the samplings.
4.2  IsolaƟ on and culƟ vaƟ on of Campylobacter spp. and E. coli 
C. coli strains (n=184) originated from fi ve Finnish pig farms in Studies I – III. Th e strains were 
used in diff erent studies as follows. In Study I, 17 isolates originating from farms 1 and 2 were 
used (primary STR-resistant isolates) to examine resistance-related mutations, and 13 isolates 
from fi ve additional pig farms were used to make STR- and ERY-resistant C. coli variants in vitro. 
In Study II, C. coli isolates were collected during six samplings at farm 3 and 147 of them were 
tested for susceptibility to STR, ERY and CIP.  Twenty-one of these isolates were characterized 
further by sequencing selected gene fragments and 133 were genotyped by restriction 
fragment length polymorphisms pulsed fi eld gel electrophoresis (RFLP-PFGE). In Study III, 
12 characterized isolates from Study II were whole genome sequenced. Additionally, 34 isolates 
originating from farms 1-3 (partly the same isolates used in Studies I and II) were screened by 
PCR for the presence of ant-like gene A in Study III.  All C. coli were isolated from pig faecal 
samples taken from the rectum with cotton swabs (Propact, Technical Service Consultants Ltd., 
Heywood, UK) and cultivated on modifi ed charcoal cefoperazone deoxycholate agar (mCCDA) 
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(CM739, Oxoid Ltd., Basingstoke, Hampshire, UK) with selective supplement (SR155, Oxoid 
Ltd.) with or without pre-enrichment in 5 ml of Bolton broth (CM983, Oxoid Ltd.). Th e C. 
upsaliensis and C. jejuni strains in Study IV were isolated from dog faeces as a three-day pooled 
sample and cultivated on mCCDA. Incubation was under microaerobic conditions (5% O2, 10% 
CO2, 85% N2 for C. coli and C. jejuni and 6% O2, 10% CO2, 5% H2, 79% N2 for C. upsaliens) at 37 
°C. Th e putative Campylobacter isolates were confi rmed as C. coli, C. jejuni or C. upsaliensis with 
species-specifi c PCR (27, 197-199). 
Th e E. coli NEB 5-alpha cells (New England Biolabs, Frankfurt, Germany) used in Study III 
were grown under normal atmospheric oxygen at 37 °C on Luria-Bertani (LB)  plates  (Difco, 
Sparks, MD, USA) supplemented with ampicillin (100 mg/l, Sigma-Aldrich, Stenheim, Germany) 
or chloramphenicol (33 mg/l, Sigma-Aldrich), as appropriate. 
All isolates were stored frozen at -70°C in either skim milk or nutrient broth (NB, Oxoid 
Ltd.) with 15-20% glycerol. C. coli, C. jejuni and C. upsaliensis were further grown on Brucella or 
Nutrient agars (NBA, Oxoid Ltd.) supplemented with 5% blood (Labema, Kerava, Finland). 
4.3  AnƟ microbial suscepƟ bility tesƟ ng 
Th e agar dilution method (according to M31-A3 NCCLS, 2002 or M45-A CLSI, 2006) was used 
in all four studies (see the last paragraph for detailed description of susceptibility testing methods 
used in each study). Briefl y, bacterial isolates were sub-cultivated twice overnight and suspended 
in Muller-Hinton Broth (MHB, Oxoid Ltd.) to make a suspension with turbidity corresponding 
to 0.5 McFarland standard. A multipoint inoculator was then used to inoculate Muller-Hinton 
agar plates (MHA, Oxoid Ltd.) supplemented with 5% blood with doubling concentrations of the 
desired antimicrobial. Th e plates were incubated microaerobically for 48 h at 37 °C, aft er which 
the results were read and MICs were recorded as the lowest concentration inhibiting all visible 
growth.
Th e broth microdilution method using VetMIC Camp (National Veterinary Institute, 
Uppsala, Sweden) microtitre plates was applied in Studies I and IV according to the procedure 
of the manufacturer. Briefl y, aft er freezing, bacterial isolates were grown twice overnight, aft er 
which suspensions with turbidity corresponding to 0.5 McFarland standard were made and 
diluted to 1:1000 in cation-adjusted MHB (Difco, Becton-Dickinson and Company, Sparks, 
USA) supplemented with 5% lysed horse blood to yield suspensions containing approximately 
105 cells. Due to the fastidious nature of some of the C. upsaliensis isolates, NB was used in place 
of cation-adjusted MHB in Study IV (30, 200). Th ese bacterial suspensions were then inoculated 
in microtitre plates, which were incubated microaerobically for 48 h at 37 °C. Th e results were 
read under a magnifying lens with a lamp and MICs were recorded as the lowest concentration 
inhibiting all visible growth in a well.
Th e E-test method used in Study I was performed according to the manufacturer’s 
instructions by preparing bacterial suspensions with turbidity corresponding to 0.5 McFarland 
standard and cotton swabs were used to spread suspension evenly on MHA plates. Th e agar was 
allowed to dry and then an E-test strip (Biomerieux-Suomi Oy, Helsinki, Finland) containing 
a concentration gradient of the desired antimicrobial was placed in the middle of the agar. Th e 
plates were incubated for 48 h at 37 °C microaerobically. MICs were recorded as the concentration 
at which the elliptical zone of no bacterial growth intersected with the strip.
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For all susceptibility assays, C. jejuni reference strain ATCC 33560 was used as a control. 
Th e ECOFF values as determined by EUCAST (www.eucast.org) were applied for each species 
as appropriate. Since no ECOFFs have been determined for C. upsaliensis, those of C. jejuni were 
applied for this species.
In Study I, the preliminary antimicrobial susceptibility testing of C. coli was carried out 
with the broth microdilution method, and STR and ERY MICs were confi rmed with E-tests or 
agar dilution. In Study II, susceptibility testing of C. coli isolates for STR (MP Biomedicals, Ill 
Cedex, France), CIP (Sigma-Aldrich) and ERY (Sigma-Aldrich) was performed with the agar 
dilution method. In Study III, MICs of C. coli for STR, CIP, ERY and spectinomycin (SPEC, 
Sigma-Aldrich) were determined with the agar dilution method. Additionally, STR susceptibility 
of selected transformant E. coli colonies was tested with the broth macrodilution method (CLSI 
M07-A9). In Study IV, the C. upsaliensis and C. jejuni isolates originating from 18 dogs were 
tested with the broth microdilution method, and STR MICs were confi rmed with the agar 
dilution method.
4.4  SelecƟ on of resistant variants by exposure to STR and ERY 
and eﬄ  ux pump inhibiƟ on assay
In Study I, 13 C. coli isolates with STR MICs of 2-4 mg/l were cultivated successively on MH 
agars with 5% blood containing increasing concentrations of STR and 20 in vitro generated STR- 
resistant colonies isolated from plates containing 8, 32 or 64 mg/l STR were selected for further 
MIC analysis. In addition, two of these in vitro acquired STR-resistant variants as well as two 
STR-susceptible C. coli isolates were used for selection of ERY-resistant variants by cultivating in 
increasing concentrations of ERY. 
Th e eff ect of effl  ux pump inhibitor phenyl-arginine-β-naphthylamine (PaβN; Sigma-
Aldrich) on STR MICs of 17 primary STR/ERY-resistant C. coli isolates in Study I was tested 
in two independent experiments using the agar dilution method. Briefl y, bacterial isolates were 
grown on MHA plates containing 1-1024 mg/l STR with and without 50 mg/l PaβN and STR 
MICs were recorded aft er 48 h of microaerobic incubation at 37 °C. As a control, the isolates 
were also cultivated on plates containing 0.5-1024 mg/l ERY with and without 50 mg/l PaβN or 
only 50 mg/l PaβN.
4.5  DNA extracƟ on, PCR, sequencing and sequence analysis 
of PCR products
Bacterial DNA was extracted with Pitcher’s method (201) (Studies I and II) or using Wizard 
Genomic DNA purifi cation kit (Promega, Madison, WI, USA) or Purelink Genomic DNA mini 
kit (Invitrogen, Carlsbad, CA, USA)  (Studies I, III and IV). Plasmid DNA was extracted with 
E.Z.N.A Plasmid Mini Kit I (Omega Bio-Tek, Norcross, GA, USA) in Study I.
In Study I, the rpsL, rsmG (known as gidB at the time), aadE, 23S rRNA gene and two rrs 
gene fragments (500 and 900 regions) from 17 primary STR/ERY-resistant C. coli isolates and the 
rpsL and aadE gene fragments from 33 STR-resistant variants and their parental isolates were 
amplifi ed and sequenced. In addition, the rrs500 fragments of fi ve C. coli variants (1.1, 6.1, 10.1, 
10.2 and 13.1, Table 6) were amplifi ed and sequenced.   In Study II, rplV, gyrA and 23S rRNA 
gene fragments were amplifi ed and sequenced from 19 and the rplD gene fragments from 12 C. 
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coli isolates. Th e sequences of rplV and rplD of the 12 whole-genome sequenced C. coli isolates in 
Study III were later confi rmed with WGS data (see below).  In Study III, the presence of ant-like 
gene A fragment was investigated from 34 C. coli isolates with STR MICs between 4 and >1024 
mg/l using primers ccoliaadE-Fw and ccoliaadE-Rw. Th e gyrA gene fragment in Study II was 
amplifi ed with primers described in (202). Th e other aforementioned primers used in Studies 
I-III are listed in Table 4.
Sequencing of amplifi ed DNA fragments in Studies I and II was carried out at the Institute of 
Biotechnology, University of Helsinki, using Sanger sequencing with automated cycle sequencer 
with Big Dye Terminator® chemistry (PE Applied Biosystems, Foster City, CA, USA).
Th e sequence data were analysed using the Staden Package (http://staden.sourceforge.
net/) and Bionumerics version 5.10 (Applied Maths NV, Sint-Martens-Latem, Belgium), and 
sequence quality was assessed with FinchTV (Geospiza Inc., Seattle, WA, USA). Consensus 
sequence alignment of Sanger-sequenced gene fragments was performed in ClustalW (EMBL-
EBI, Cambridge, UK).
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4.6  RFLP-PFGE typing 
In Study II, RFLP-PFGE typing of 133 isolates originating from 12 pigs from group A and 12 pigs 
from group B was performed as described previously (27) using SmaI with or without additional 
digestion with KpnI. Th e banding patterns were analysed with the soft ware Bionumerics and 
isolates with similarity less than 90% in the dendrogram or a minimum diff erence of one band 
were classifi ed as diff erent genotypes.
4.7  Whole-genome sequencing, assembly and annotaƟ on 
In Studies III and IV, WGS was performed for 12 C. coli isolates from pigs and for 24 C. 
upsaliensis and two C. jejuni isolates from dogs, respectively. Further, in Study III, two C. coli 
natural transformants and a spontaneous mutant were also whole-genome-sequenced. Draft  
whole-genome sequences were determined using Illumina Miseq or Hiseq technology (Nextera 
XT library paired end kit) at the Institute for Molecular Medicine (FIMM) Technology Centre, 
University of Helsinki. Th e paired end reads were assembled into contigs using Spades 3.1.1 
or 3.2.0 (188). Genomes were annotated in RAST (191) and analysed with whole-genome 
multilocus sequence typing (wg-MLST) using genome profi ler, GEP (203).
Th e sequences of gyrA, rsmG, rpsL and rrs of C. upsaliensis in Study IV were BLAST-
searched, translated in EMBOSS Transeq (http://www.ebi.ac.uk/Tools/st/emboss_transeq/) and 
aligned in MUSCLE (http://www.ebi.ac.uk/Tools/msa/muscle/). Th e sequences were compared 
with that of C. upsaliensis RM3195, known to be susceptible to STR and resistant to NAL, but 
with no quinolone resistance-associated mutations in gyrA (29).
Homologues of putative STR resistance genes in the three intermediately STR-resistant 
whole-genome-sequenced C. coli in Study III and the 24 C. upsaliensis in Study IV were BLAST-
searched using known sequences of these genes. Further, for this thesis, using WGS data, the 
sequences of rplV and rplD of 12 whole-genome-sequenced C. coli isolates were confi rmed and 
the rsmG sequences of the same 12 C. coli were evaluated. 
4.8  Screening, evoluƟ onary analysis and enzyme modelling of 
Campylobacter ant-like gene A
In Study III, the presence of Campylobacter ant-like gene A was screened by PCR with the 
primers ccoliaadE-Fw and ccoliaadE-Rw from 34 C. coli isolates originating from farms 1-3 
and having variable STR MICs. In addition, whole-genome sequences of ≈500 Finnish C. jejuni 
strains from several sources sequenced in other projects (204-206) were screened in silico for 
orthologues of ant-like gene A (peg 1084 from C. coli 47.4) using 40% cut-off  value of the BLAST 
score ratio (207).
Altogether, 130 homologous sequences of ant-like gene A product were retrieved from NCBI 
nr database with blastX (http://blast.ncbi.nlm.nih.gov). Th ese sequences were aligned using 
MAFFT (208), and evolutionary history was inferred in MEGA5.3 (209) using the Minimum 
Evolutionary Method (210). Th e resulting consensus tree was condensed at 95% bootstrap values 
and edited in iTOL web server (211).
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Structural models of the ANT-like proteins A and B from C. coli 47.4 and C. jejuni 12xb_914 
in Study III were built in the fully automated PHYRE2 server (212, 213), and catalytic site 
detection and conservation analysis were performed with Phyre2 investigator (213) using the 
ANT(6) from Bacillus subtilis as a reference structure.
4.9  Expression of ant-like genes in E. coli and construcƟ on of 
47.4∆ant(A)::CAT mutant
Expression of ant-like genes A and B in E. coli and construction of 47.4Δant(A)::CAT (Study III) 
have been schematically represented in Fig. 6. Th e ant-like genes A and B with putative promotor 
regions were fi rst amplifi ed by PCR with primers aadE-A-AF-KpnI and aadE-A-AR-PstI (C. coli 
47.4) or ant60-A-AF-KpnI and ant60-A-AR-PstI (C. jejuni FB01514), respectively (Table 4), which 
also introduced restriction sites at each end. Each gene was then cloned into plasmid pUC119 to 
create pUC119antA or pUC119antB and transformed into chemically competent E. coli grown 
on LBA (Luria-Bertani agar) with 100 mg/l ampicillin. Positive transformants with plasmid 
containing the correct insert were confi rmed by colony PCR with primers CcoliaadE-Fw and 
Ccoli-aadE-Rw (gene A) or by detecting correctly sized fragments aft er restriction-digestion with 
KpnI and PstI (gene B). Selected transformants were then tested for STR susceptibility by broth 
dilution (CLSI M07-A9). Th e amplifi ed pUC119-ant(A) was  isolated and used as a template for 
inverse PCR using primers aadE-A-IF-BamHI and aadE-A-IR-SalI (Table 4), creating linear DNA 
with restriction sites, and the CAT (chloramphenicol acetyltransferase) cassette with the same 
restriction sites was then ligated into this plasmid to obtain closed pUC119Δant(A)::CAT. Th is 
construct was amplifi ed in E. coli grown on LBA with 33 mg/l chloramphenicol and introduced 
as a suicide plasmid into electrocompetent C. coli 47.4. With C. coli replication, the construct 
was inserted into the genome by homologous recombination and mutants were selected on NBA 
supplemented with 12.5 μg/ml chloramphenicol.
4.10  Natural transformaƟ on assays
In Study III, the natural transformability of the Campylobacter ant-like gene A was investigated. 
C. coli strain 18.3, susceptible to STR, was used as a recipient and DNA from C. coli isolate 47.4 
was used as a donor in the natural transformation assays modifi ed from previous studies (214, 
215). Briefl y, the recipients were incubated overnight in 2 ml of NB and the optical density 
(OD600) was subsequently adjusted to 0.2 and 500 μl of adjusted suspension was added to test 
tubes containing NBA with a slanted surface. Th e tubes were incubated for three hours at 37 °C 
microaerobically and subsequently 2 μg of donor DNA diluted in a 10 μl volume was added to 
the recipient. Th e same volume of peptone water was added to the control tube to account for 
spontaneous mutations. Incubation was continued for three hours (one replication cycle), and 
bacterial suspensions were then cultivated on NBA containing 64 or 32 mg/l STR. Th e STR MICs 
and the presence of ant-like gene A were studied from selected transformants and spontaneous 
mutants by PCR using primers CcoliaadE-Fw and CcoliaadE-Rw (Table 4). Further, two natural 
transformants and a spontaneous mutant were whole-genome-sequenced as described above 
and analysed using wgMLST (GeP).
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4.11  StaƟ sƟ cal analyses
SPSS for Windows, Rel. 15.0.1. (SPSS Inc., Chicago, IL, USA) was used for statistical analyses. 
Fischer’s exact test or Chi-squared test was used to test for statistically signifi cant diff erences 
(P<0.05) in the prevalence of resistance among C. coli isolates between samplings and groups in 
Study II.
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5  RESULTS
5.1  CharacterizaƟ on of anƟ microbial resistance of porcine 
C. coli (I-III)
5.1.1  STR resistance-associated muta? ons in rpsL (I-III)
All analysed highly STR-resistant (MIC>1024 mg/l) C. coli isolates from pigs in Studies I-III 
(n=15) had A128G missense mutation in rpsL, leading to predicted K43R (Lysine43Arginine) 
substitution in ribosomal protein S12, but none of the studied eight STR-susceptible or of the 
six intermediately STR resistant (MIC 128-512 mg/l) C. coli had resistance associated mutations 
in codons 43 or 88 of rpsL (Table 5).  No other nonsynonymous mutations were detected in the 
sequenced fractions of rpsL.
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Th e in vitro-generated STR resistant variants in Study I had more heterogeneous STR 
MICs and mutations in rpsL, but A128G being also the most frequently detected (n=9) followed 
by A263G (K88R, n=4, Table 6). Together these two transitions covered 65% of all detected 
mutations. In addition, transversion A262C (K88Q, Lysine88Glutamine) was detected in one 
highly STR-resistant mutant and transition A262G (K88E, Lysine88Glutamic acid) in two 
variants with STR MICs of 32 mg/l and >1024 mg/l. Altogether three in vitro-generated variants 
with STR MICs 32-128 mg/l had no change in either codon. However, variants 1.1, 6.1 and 6.2 
and variants 10.2, 11.1 and 12.1 had nonsynonymous mutation A256G or G257A in rpsL leading 
to substitutions R86G (Arginine86Glysine) and R86K (Arginine86Lysine) in S12, respectively 
(previously unpublished). Further, in Study III, the spontaneous rpsL mutant C. coli A.2 acquired 
in the natural transformation experiments and having STR MIC >1024 mg/l was found to 
harbour both A128C and A129T transversions in rpsL, resulting in K43T (Lysine43Th reonine) 
change in S12 (not shown). 
Table 6. MICs and changes in codons 43 and 88 of S12 of in vitro STR resistant C. coli variants.
    MIC (mg/l) S121
Study Isolate1 STR ERY Codon 43 Codon 88
I 1.1 32 0.25 K K
1.2 >1024 0.25 K R
2.1 >1024 ≤0.063 K R
2.2 >1024 ≤0.063 K R
3.1 >1024 ≤0.063 K R
4.1 >1024 0.25 R K
5.1 >1024 0.125 K E
6.1 64 0.25 K K
6.2 >1024 0.25 K Q
7.1 >1024 0.25 R K
8.1 >1024 0.5 R K
8.2 >1024 2 R K
8.3 >1024 1 R K
9.1 >1024 4 R K
9.2 >1024 4 R K
10.1 4 1 K K
10.2 128 4 K K
11.1 >1024 4 R K
12.1 >1024 0.5 R K
  13.1 32 0.5 K E
1 K: Lysine, R: Arginine, E: Glutamic acid, Q: Glutamine
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5.1.2  Other STR resistance-associated muta? ons studied in C. coli (I, III)
In Study I, no mutations in the rpsL codon 43 and 88 were detected in three intermediately STR-
resistant isolates from pigs and in the three in vitro-generated C. coli variants, also intermediately 
STR-resistant, so additional genes were screened.  However, no truncation in rsmG or previously 
described resistance-associated mutations in the 500 or 900 regions of rrs gene were detected 
as compared with susceptible isolates and C. coli RM2228, and no gene product was obtained 
with the primers aadEF Full and aadER Full (Table 4) from the 17 STR- and/or ERY-resistant 
C. coli isolates from pigs from farms 1 and 2 (Table 5). Also, no PCR product was obtained with 
the aforementioned primers from the plasmid or chromosomal DNA of any of the in vitro STR-
resistant variants and no mutations were seen in the sequenced 500-region of the rrs gene in the 
fi ve in vitro-generated intermediately STR resistant variants as compared with their susceptible 
parent isolates. Th e sequences of rsmG were additionally analysed from the 12 whole-genome-
sequenced C. coli from Study III (bolded in Table 5). Also among these isolates, identical 
sequences were found regardless of the resistance level.
5.1.3  Mechanism and occurrence of intermediate STR resistance (III)
5.1.3.1  Occurrence and locaƟ on of ant-like genes A and B
Twelve C. coli isolates with various STR resistance levels from farm 3 were whole-genome-
sequenced (bolded in Table 5). Each of the three isolates exhibiting intermediate-level resistance 
to STR (MIC 256-512 mg/l) was found to harbour an ant(6)-resembling gene (referred as ant-
like gene A) encoding a putative adenylyltransferase. Th e presence of this gene (peg1084 of C. coli 
47.4) was further screened by PCR from 34 C. coli isolates originating from farms 1-3. All isolates 
with an intermediate level of STR resistance (n=10, originating from farms 2 and 3) yielded the 
right-sized amplicon. Th ese included also isolates 17, 20 and 21 from farm 2 (Table 5), which had 
yielded a negative result with primers aadEF Full and aadER Full in Study I (Table 4). 
Additionally, a 60% homologue of ant-like gene A (referred as ant-like gene B) was 
detected in 19 (≈4%) of the in silico screened genome sequences of C. jejuni isolates from our 
strain collection, but the presence of this homologue was not associated with STR resistance. 
Both genes, encoding ANT-like protein A in C. coli and protein B in C. jejuni, were located in a 
similar position in the chromosome corresponding to hypervariable region 14 described in C. 
jejuni NCTC 11168, which contains also a restriction-modifi cation locus and genes encoding 
oxidoreductases, hydrolases, dehydrogenases and decarboxylases, among others (56).
Th e WGS data of twelve C. coli isolates from farm 3 (Table 5) were analysed with wgMLST. 
Th e three isolates harbouring ant-like A gene were two diff erent strains as >1000 allelic 
diff erences were detected in wgMLST while the four highly STR-resistant isolates clustered 
together, forming a single strain.
5.1.3.2  EvoluƟ onary analysis of ant-like gene A and enzyme modelling 
A cladogram was built using the 130 closest homologues of ant-like gene A (peg 1084 of C. coli 
47.4) retrieved from NCBI nr database with BlastX (see Study III, Fig. 3). Th e ANT-like protein 
A was found in a monophyletic clade, and it was detected solely in C. coli strains originating from 
several countries and hosts. Th e countries included the UK, Switzerland and the United States, 
and hosts and sources were ducks, chickens, pigs, environment and humans. A sister clade was 
found to include proteins similar to ANT-like protein B, and they were found in both C. jejuni and 
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C. coli. Several aminoglycoside 6-adenylyltransferase homologs described in Campylobacter spp. 
in previous studies were located in a polychotomous clade together with homologous proteins 
originating from Gram-positive bacterial species, including Streptococcus spp., Enterococcus spp., 
Bacillus spp. and Clostridium spp. Both ANT-like proteins A and B resembled the structure of 
aminoglycoside 6-adenylyltransferase from B. subtilis (accession PDB:2PBE) and lincosamide 
adenylyltransferase LinB from Staphylococcus aureus (115), albeit with a low amino acid identity. 
Further, the ANT-like protein A was found to share only low (<40%) amino acid identity and 
blast score ratios (0.11-0.24) with the previously described adenylyltransferases.
5.1.3.3  47.4∆antA::CAT constructs and expression of ant-like genes in E. coli
Th e ant-like genes A and B were expressed in E. coli and STR MICs of E. coli isolates harbouring 
plasmid  pUC119-antA (n=7) were found to increase 4- or >8-fold (16→64->128 mg/l), but no 
change in STR MIC was seen in E. coli harbouring pUC119-antB. Th e studied knock-out mutant 
colonies (n=14) of C. coli 47.4 with CAT cassette inserted in ant-like gene A (Fig. 7) showed a 
64-fold decrease in STR MIC (256→4 mg/l). No changes in the MICs for SPEC, CIP or ERY were 
observed in studied mutants as compared with the WT C. coli 47.4. 
5.1.3.4  Natural transformaƟ on assays
Two and 113 natural transformants were obtained from STR-susceptible C. coli recipient 18.3 
(MIC STR 4 mg/l) in assays using 64 and 32 mg/l of STR for selection, respectively, and all tested 
transformants (n=9) were intermediately resistant to STR (MIC 64-512 mg/l). Altogether, one 
and three spontaneous mutants were generated in the same experiments, respectively, all having 
STR MICs >1024 mg/l. Th e genomes of two natural transformants and a spontaneous mutant 
were sequenced and analysed using wgMLST (GeP) with the genome of C. coli 47.4 used as a 
reference. Th e genetic exchange detected in the natural transformants as compared with the 
donor (47.4) and recipient (18.3) has been summarized in Tables 7 and 8. In both transformants, 
several genes in addition to ant-like gene A were found to be transferred from the donor, 
including also regions outside of the hypervariable region 14. A total of 24 genes in 8 regions and 
18 genes in 5 regions were found to transfer from the donor to the recipient in A+.1 and A+.2, 
respectively.
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Table 7. Genetic fl ow observed in the C. coli natural transformant A+.1 in GeP analysis.
Donor 47.41 Recipient 18.31 A+.11 peg2 Annotation3
1 2 1 121 FIG00469778: hypothetical protein
1 2 1 122 FIG00469817: hypothetical protein
1 2 3 128 L-lactate permease
1 T 1 135 Uracil-DNA glycosylase, family 1
1 2 3 157 FIG00470444: hypothetical protein
1 2 1 304 ATP-dependent Clp protease adaptor protein ClpS
1 2 1 305 Possible periplasmic thioredoxin
1 2 1 306 tmRNA-binding protein SmpB
1 2 1 307 4-diphosphocytidyl-2-C-methyl-D-erythritol kinase (EC 2.7.1.148)
1 2 D 874 hypothetical protein
1 2 1 901 Gene SCO4494, oft en clustered with genes in menaquinone via futalosine pathway
1 2 1 904 putative periplasmic protein (vacJ homolog)
1 2 1 906 membrane protein
1 2 3 1082 sarcosine oxidase, putative
1 M 1 1083 NAD(P)H oxidoreductase YRKL (EC 1.6.99.-) 
1 M 1 1084 ant-like gene A
1 M 1 1085 RecD-like DNA helicase YrrC
1 T 1 1086 Uncharacterized conserved protein
1 M 1 1087 Dienelactone hydrolase and related enzymes
1 M 1 1088 oxidoreductase of aldo/keto reductase family, subgroup 1
1 M 1 1089 transporter, putative
1 M 1 1090 conserved protein
1 2 1 1091 Arsenical resistance operon repressor
1 2 1 1092 Arsenate reductase (EC 1.20.4.1)
1Allele  type; 1= donor, 2= recipient, 3= new, M= missing, T= truncated, D= doubled (203)
2Peg numbering according to the genome of 47.4.gbk used as a reference
3Annotation in RAST (191)
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Table 8. Genetic fl ow observed in the C. coli natural transformant A+.2 in GeP analysis.
Donor 47.4 Recipient 18.31 A+.21 peg2 Annotation3
1 T 1 135 Uracil-DNA glycosylase, family 1
1 2 T 185 Ribbon-helix-helix protein, copG family domain protein
1 2 D 874 hypothetical protein
1 2 1 1079 MloA protein, putative
1 2 1 1080 Type I restriction-modifi cation system, DNA-methyltransferase subunit M (EC 2.1.1.72)
1 2 1 1081 hypothetical protein
1 2 4 1082 sarcosine oxidase, putative
1 M 1 1083 NAD(P)H oxidoreductase YRKL (EC 1.6.99.-) 
1 M 1 1084 ant-like gene A
1 M 1 1085 RecD-like DNA helicase YrrC
1 T 1 1086 Uncharacterized conserved protein
1 M 1 1087 Dienelactone hydrolase and related enzymes
1 M 1 1088 oxidoreductase of aldo/keto reductase family, subgroup 1
1 M 1 1089 transporter, putative
1 M 1 1090 conserved protein
1 2 1 1091 Arsenical resistance operon repressor
1 2 1 1092 Arsenate reductase (EC 1.20.4.1)
1 2 1 1571 Methionyl-tRNA synthetase (EC 6.1.1.10)
1Allele  type; 1= donor, 2= recipient, 4= new, M= missing, T= truncated, D= doubled (203)
2Peg numbering according to the genome of 47.4.gbk used as a reference
3Annotation in RAST (191)
5.1.4  Muta? ons associated with ERY and CIP resistance (I, II)
All of the studied C. coli isolates highly resistant to ERY (MIC≥512 mg/l, n=16) had A2122G 
mutation in the 23S rRNA encoding gene, but this mutation was not detected in the low-
level resistant isolates (ERY MIC 16-32 mg/l, n=11) (Table 5). Further, in Study II, no ERY 
resistance-associated mutations in the genes rplV (coding for ribosomal protein L22) and rplD 
(encoding ribosomal protein L4) were found, including analysed isolates with ERY MIC values 
of 16–32 mg/l (n=9) (Table 5). 
All CIP resistant C. coli isolates (MIC 32-128 mg/l, n=7) from pigs from farm 3, where 
DANO was used, had a commonly described C257T mutation in gyrA, resulting in T86I 
substitution in DNA gyrase (Table 5). 
5.1.5  Associa? ons between STR and ERY resistance (I)
As a statistically signifi cant increase was seen in the number of STR resistant isolates aft er tylosin 
treatment of pigs in a previous farm study (27) the putative associations were examined in Study 
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I. Th e STR MIC of an initially STR-susceptible C. coli isolate did not increase with exposure 
to increasing concentrations of ERY even when the generated variants were resistant to ERY 
(MIC>256 mg/l) and no increase in ERY MICs were observed in the in vitro-generated STR-
resistant variants. No diff erences in the STR MICs of the primary STR- and/or ERY-resistant C. 
coli isolates (n=17) were seen with or without the effl  ux pump inhibitor PaβN, while the ERY 
MICs decreased on average fourfold.
5.1.6  Dynamics of STR resistance in C. coli a? er DANO and tylosin 
treatments (II, III)
Th e occurrence of STR resistance was monitored along with resistance to CIP and ERY of 147 
C. coli isolates in Study II (published as supplemental material in Study III) as pigs were treated 
consecutively with DANO (group A, n=12 animals) and tylosin (groups A+B, in group B, n=15 
animals). Th e results are summarized in Table 9. Diff ering from EUCAST ECOFFs, isolates with 
STR MIC of 8 mg/l were classifi ed as susceptible since a clear division was observed with C. coli 
isolates having STR MICs of either 4-8 mg/l or ≥256 mg/l in this and in our previous study (27).
While no STR resistance was detected among C. coli isolated before weaning (sampling 
I, n=22), a common resistance pattern already aft er weaning (samplings II and III) was STR 
resistance (12/48, 25%). Th e occurrence of STR-resistant isolates increased aft er DANO treatment 
(samplings IV and V) in the group A (n=16/22, 73% P<0.01), and the proportion of these isolates 
was higher in group A than in group B (n=9/28, 32%, P<0.01). Aft er tylosin treatment (sampling 
VI) the proportion of STR-resistant isolates decreased in group A (P<0.05) while no statistically 
signifi cant change was seen in group B or between the groups (Table 9). 
Table 9. Distribution of STR MICs aft er DANO and tylosin treatments of pigs in Study II.
Sampling Pig groupa
No. of isolates with MIC (mg/l) of: No. (%) of 
resistant isolates1 2 4 8 16 32 64 128 256 512 ≥1024
I A 8 1 0 (0.0)
B 9 4 0 (0.0)
II A 6 2 1 1 (11.1)
B 6 4 1 1 1 3 (23.1)
IIIb A 1 4 2 4 4 (36.4)
B 9 2 1 3 4 (26.7)
IV A 1 1 1 8 9 (81.8)
B 7 3 5 5 (33.3)
Vc A 4 7 7 (63.6)
B 6 3 4 4 (30.8)
VI A 5 3 4 4 (33.3)
B 5 4 1 3 2 6 (40.0)
Vertical line indicates the breakpoint used in this study 
aA, DANO-treated pigs; B, control pigs
ba three-day DANO treatment for group A aft er sampling III
ca ten-day tylosin treatment for group A and B aft er sampling V 
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In study II, RFLP-PFGE typing of 133 isolates originating from 12 pigs from group A and 12 pigs 
from group B was performed. Most of the STR-resistant isolates were also resistant to at least one 
other antimicrobial studied (CIP, ERY), and 29/41 (70%) of the genotyped STR-resistant isolates 
had the same PFGE type 1 which was always highly STR-resistant (MIC>512 mg/l), but isolates 
having this genotype had resistance patterns STR, STR-CIP or STR-CIP-ERY. While high-level 
STR resistance occurred also in another PFGE type, type 11 (n=5, exhibiting resistance patterns 
STR or STR-ERY), the intermediately STR-resistant isolates (MIC 256-512 mg/l, n=6) had three 
diff erent genotypes, (PFGE: 2, STR-CIP; PFGE: 21, STR/STR-CIP; PFGE: 19, STR-CIP-ERY). 
High and intermediate level STR-resistant isolates were never found to have same PFGE-types.
5.2  Resistance in canine C. upsaliensis and C. jejuni strains (IV)
5.2.1  Occurrence of resistance
Antimicrobial resistance against STR, ERY, CIP, NAL, tetracycline and gentamicin of two C. 
jejuni and 24 C. upsaliensis isolates originating from 18 Finnish Staff ordshire bull terriers was 
evaluated. Both C. jejuni isolates were susceptible to all the tested antimicrobials while, among C. 
upsaliensis, a high rate of STR resistance was observed with 19/24 isolates (79.2%) having MICs 
of > 4 mg/l (Table 10) and one isolate (4.2%) having increased MIC for NAL and CIP. Resistance 
against other antimicrobials was not detected in C. upsaliensis. Isolates that originated from the 
same dog in two consecutive samplings and had the same STs (DR15S and DR15S_2; DR18S and 
DR18S_2; DR44S and DR44S_2; DR55S and DR55S_2, Table 10) always had also the same STR 
MICs. 
5.2.2  Muta? ons in STR and quinolone resistant C. upsaliensis
Th e amino acid changes corresponding to missense mutations in rpsL codons 43 and 88 and the 
observed deletions, insertions and truncation caused by frameshift  mutations in C. upsaliensis 
rsmG are shown in Table 10. In all low- (MIC 16 mg/l, n=12) and high-level (MIC≥1024 mg/l, n=7) 
STR-resistant C. upsaliensis isolates, a missense mutation A263G in rpsL corresponding to amino 
acid change K88R was detected. In addition, in all highly STR-resistant isolates, various nucleotide 
deletions and insertions were seen in the sequence of rsmG, leading to frameshift  and termination 
immediately downstream of the mutation site at amino acids 13, 49, 137, 139, 144 or 155 of the total 
of 191 amino acids of C. upsaliensis rsmG. All of these mutants also harboured A263G change in rpsL 
and had high STR MICs (≥1024 mg/l). Also some truncation of rsmG was observed in a part of the 
STR-susceptible and low-level resistant isolates, but only the last 3-5 amino acids were lost in these 
cases. In contrast, none of the STR-susceptible strains (MIC 0.5-2 mg/l, n=5) had STR resistance-
associated mutations in rpsL or a signifi cant truncation of rsmG (Table 10). Moreover, several other 
nucleotide substitutions in rsmG as compared to the sequence of C. upsaliensis RM3195, leading to 
various amino acid substitutions in the predicted sequence of RsmG, were observed in all isolates 
regardless of the STR MIC-level. Further, no resistance-associated mutations in rrs were found and 
no other AME-encoding genes associated with STR resistance were detected in the C. upsaliensis 
annotated genomes to explain the observed resistance levels.
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One C. upsaliensis isolate (DR22S, Table 10) with slightly elevated MIC for CIP and 
resistant to NAL had C257T transition on gyrA leading to T86M (Th reonine86Methionine) 
change. Further, another isolate (DR5S, previously unpublished) not included in Study IV due 
to it originating from a dog sampled only once had similar levels of quinolone resistance and 
harboured the same mutation in gyrA and is therefore included in Table 10, but not in the 
occurrence analysis.
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6  DISCUSSION
6.1  STR resistance in C. coli and C. upsaliensis
6.1.1  C. coli
We were the fi rst to associate mutations in codons 43 and 88 (C. coli numbering) of the rpsL gene 
with STR resistance in C. coli, a fi nding concordant with previous fi ndings in other bacterial 
species, such as E. coli, M. tuberculosis and H. pylori (122, 125, 126). Th is shared resistance 
mechanism between species is due to the unique way that streptomycin interacts with the 
bacterial 30S ribosomal structures and, unlike other aminoglycosides, makes contact also with 
the ribosomal protein S12 (63).
In our studies, mutation in rpsL leading to predicted substitution K43R in C. coli ribosomal 
protein S12 were associated with a high level of streptomycin resistance (MIC>1024 mg/l) 
and this was the only rpsL mutation detected in isolates from pigs. Mutations leading to other 
changes than K43R were observed only in the in vitro-generated C. coli variants and occurred 
mainly in codon 88, leading to more heterogeneous streptomycin MICs, as also described in E. 
coli and M. tuberculosis (122, 216, 217). Th e K88E substitution was detected in two variants with 
streptomycin MICs of 1024 and 32 mg/l. Similar observations have been made in M. tuberculosis 
in which K88R mutants were found to have STR MICs of 16, 256 and 1024 mg/l (217). Th is 
diff erence in MICs indicates that also other mechanisms could be involved in the higher level 
resistance phenotype, which could be, for example, mutations in rsmG. RsmG is a conserved 
methyltransferase that catalyses the methylation of G527 in 16S rRNA, a nucleotide that is in 
direct contact with STR (63, 127). Loss of function of RsmG has been shown to lead to a low level 
of STR resistance and to high rates of emergence of highly streptomycin-resistant mutants in 
several bacterial species including E. coli, Bacillus subtilis and M. tuberculosis, but having no eff ect 
on viability or growth rate (127, 128, 130). Observed resistance could be the result of reduced 
affi  nity of streptomycin to the unmethylated ribosome or increased translational accuracy 
(127, 128). Even though no truncation of rsmG was detected among the analysed isolates with 
various STR MICs from farms 1-3, the STR-resistant isolates harboured either ant-like gene A 
or mutation in rpsL, explaining their resistance level. Th e possibility that resistance-conferring 
mutations in this gene would not have been present in the in vitro-generated variants cannot be 
excluded and warrants further study. We also observed three in vitro-generated C. coli variants 
with streptomycin MICs of 32-128 mg/l which had no resistance-associated mutations in rpsL 
codons 43 or 88. However, they had nonsynonymous mutations not seen in their parent isolates 
leading to amino acid substitutions in codon 86, which could contribute to the intermediate 
streptomycin resistant phenotype. 
Streptomycin resistance-conferring mutations in rpsL have been characterized as restrictive 
(increased translational accuracy through increased ribosomal binding affi  nity due to ribosomal 
conformation changes), such as K42/43T, and non-restrictive, the only known example 
being K42/43R (218-223). Th e restrictive type manifests as a hyper accurate phenotype, and 
consequently, a slower protein translation rate, leading to even STR dependence, whereas the 
non-restrictive phenotype does not diff er signifi cantly from the wild-type ribosomes in protein 
translation rate (221, 223, 224). We did not observe rpsL mutations classifi ed as restrictive in 
isolates from pigs. Indeed, all mutations found in C. coli isolates highly resistant to streptomycin 
in vivo (e.g. from pigs) were of the non-restrictive type, which is not surprising. A small fi tness 
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cost of the K42R (corresponding to K43R in C. coli) substitution in vitro has been reported in 
E. coli, but it was not seen when these isolates were inoculated into piglets (225). Further, in a 
mouse model even a minor fi tness advantage was observed in Salmonella Typhimurium having 
K42R substitution in S12 as compared with the wild-type strain (226). However, also, Salmonella 
Typhimurium strains with mutation in rpsL leading to K42N substitution in S12 and restrictive 
phenotype, were found to develop compensatory mutations in a number of genes aft er several 
passages in vitro, and these mutations partially restored fi tness (227). Similar results have also 
been observed in E. coli (219). Curiously, S. Typhimurium with K42N amino acid substitution 
in S12 was shown to grow faster than the wild type with poor carbon source conditions in vitro 
(228). Although there is one streptomycin-containing drug currently registered for use in piglets 
and calves in Finland, veterinary streptomycin consumption is at a low level, with annual sales 
of only slightly exceeding 100 kg (of active substance) (Table 2). Th e persistent presence of 
streptomycin-resistant C. coli strains at pig farms found in our studies could be a consequence of 
the rpsL mutation leading to K43R in S12 incurring no, low or an easily compensated fi tness cost 
also in C. coli.
Interestingly, the K87/88E mutation has been associated with increased protein or antibiotic 
production rate in the late growth phase in Streptomyces spp. and E. coli which is suggested to be 
due to increased stability of the bacterial ribosome (218, 229, 230). Whether K88E substitution 
aff ects the late growth phase protein synthesis rates in Campylobacter spp. remains to be 
elucidated.  
As several intermediately streptomycin-resistant C. coli isolates with no obvious resistance-
conferring mutations or genes were detected in Studies I and II, we used the NGS approach to 
further examine the potential genetic mechanism(s). A novel streptomycin resistance-conferring 
gene, encoding a protein homologous to (albeit at the low level of <40%) the ANT(6) class of 
aminoglycoside-modifying enzymes, was found and further screening revealed its presence 
in all of the studied intermediately resistant C. coli isolates. A second phylogenetically close 
homologue (60% amino acid identity) was detected in C. jejuni and C. coli isolates, but we did not 
fi nd evidence of its association with streptomycin resistance. Both ant-like genes were located in 
similar positions in the C. coli and C. jejuni genomes, corresponding to the previously described 
hypervariable region 14 in C. jejuni, which is characterized by a restriction-modifi cation locus 
(56). Th ese hypervariable genomic regions contain genes that are considered to be part of the 
Campylobacter accessory genome, but the corresponding genomic regions in C. coli remain 
largely uncharacterized. It has been proposed that these areas would not diff er signifi cantly in 
GC content from the rest of the genome in C. jejuni (57) and could be the result of horizontal 
gene transfer inside the species by homologous recombination (56), but more studies are needed 
to shed light on the dynamics of gene transfer in these regions. 
AMEs have been found to be very heterogeneous, forming several subfamilies and groups, 
and many of them share only the ability to inactivate one or several aminoglycosides. In 
particular, adenylyltransferases have been found to share only little amino acid sequence identity 
with the other enzymes or with each other (109, 110, 112). Lincosamide and aminoglycoside 
nucleotidyltransferases have been previously proposed to be related to ancient nucleotide 
polymerases and further hypothesized that they have arisen from these so-called proto-resistant 
elements through divergent evolution (115, 231). Phylogenetic analysis revealed the presence of 
ant-like gene A only in a clade consisting of homologous proteins in C. coli derived from several 
sources and locations, including chicken, human and environmental sources and the countries 
United States, Switzerland and the UK. Among the screened C. coli isolates from our isolate 
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collection, this gene was found in isolates from 2/3 studied farms and included also the three 
intermediately streptomycin-resistant isolates from farm 2 that did not contain a previously 
described aminoglycoside adenylyltransferase gene found in a MDR plasmid in C. jejuni (24). 
Based on the phylogenetic analysis and the lack of insertion elements or other resistance genes 
in the region and the GC content being close to that of Campylobacter genome, we did not fi nd 
evidence of a recent jump of this gene to Campylobacter spp.  from another species. Th erefore, it 
can be hypothesized that ant-like gene A evolved in Campylobacter spp. from a proto-resistance 
element originally having a diff erent substrate/function.
A multidrug-resistant phenotype has been linked to most of the previously detected 
aminoglycoside resistance genes in Campylobacter spp. due to their location in MDR plasmids 
or genomic islands (24, 25, 68), but this does not seem to be the case with ant-like gene A, as no 
other known resistance genes were detected in the close proximity. We were also able to transfer 
ant-like gene A to another C. coli isolate by natural transformation, indicating that this might 
occur also in vivo in fi eld conditions. 
In conclusion, we were able to associate two mechanisms with high and intermediate 
streptomycin resistance in C. coli isolated from pigs in fi eld conditions. Curiously, the ant-like 
gene A and streptomycin resistance-associated mutations in rpsL were not present concurrently 
in C. coli isolates. Further, our genotyping data from farm 3 shows, that high and intermediate 
level streptomycin resistance occurred consistently in diff erent PFGE-types. Th is might indicate 
that an intermediate level of streptomycin resistance (e.g. harbouring aminoglycoside modifying 
enzyme encoding gene) is not required for the development of high level of streptomycin 
resistance (rpsL mutants) in vivo. 
6.1.2  C. upsaliensis
Interestingly, in streptomycin-resistant canine C. upsaliensis, we did not observe any mutations 
in rpsL leading to the non-restrictive change K43R, which was the only phenotype found in the 
STR-resistant C. coli from pigs. Instead, mutations leading to amino acid change K88R in S12 
were observed in all of the studied STR-resistant isolates (accounting for 79% of all C. upsaliensis 
isolates included in Study IV), and this mutation was found in isolates having both low (16 mg/l) 
and high (>1024 mg/l) streptomycin MICs. Th is mutation has been classifi ed as semi-restrictive 
in E. coli, resulting in only small decreases in protein synthesis rate (221, 222). In addition to 
the rpsL mutation, all highly streptomycin-resistant isolates harboured frameshift  mutations in 
rsmG, leading to a major truncation and probable loss of function of the gene product. Consistent 
with our observations in C. upsaliensis, rpsL rsmG double mutants have been associated with a 
high level of streptomycin resistance in several other bacterial species including M. tuberculosis, 
Bacillus subtilis and E. coli (127, 128, 130).
We detected also isolates susceptible to streptomycin (MIC<4 mg/l)  and not harbouring 
any resistance-associated mutations in rpsL or rsmG implying that streptomycin resistance is 
not intrinsic in this species as suggested previously (28). Th is is also supported by the fi ndings 
of Fouts et al. (2005) (29) that C. upsaliensis strain RM3195 was not resistant to streptomycin. 
However, it can be presumed that the streptomycin resistance phenotype among canine C. 
upsaliensis isolates is quite persistent not only based on the prevalence data but also on the same 
phenotype (and resistance-conferring mutation) being observed in isolates acquired from the 
same dogs 4-5 months apart in each of the four cases when the dog had retained C. upsaliensis 
with the same ST. 
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6.2  Quinolone resistance mutaƟ ons in C. coli and 
C. upsaliensis and ERY resistance mutaƟ ons in C. coli 
While T86I is the most commonly described amino acid substitution in GyrA in C. jejuni and 
C. coli, various other substitutions have also been described (Th r86Lys, Asp90Asn, Asp90Ala, 
Asp90His, Asp90Tyr, Ala87Pro, Ala70Th r, Th r86Ala, Th r86Val), many of them associated  with 
a low level of fl uoroquinolone resistance or resistance to nalidixic acid only (149-151, 153-
156).  All ciprofl oxacin-resistant C. coli isolates from farm 3, where danofl oxacin was used, 
were found to harbour C257T mutation in gyrA, leading to amino acid substitution T86I, but 
no other mutations in the QRDR region were detected, indicating that danofl oxacin does not 
induce novel mutations in the gyrA in C. coli in vivo. Th e same mutation was also found in two 
C. upsaliensis isolates with a slight increase in ciprofl oxacin MICs but resistant to nalidixic acid. 
Th is is explained by the fact that C257T mutation leads to the substitution T86M in C. upsaliensis 
due to diff ering nucleotide sequences of gyrA between C. upsaliensis and C. coli. T86M is a novel 
substitution which has not been described previously in Campylobacter species. Interestingly, 
Fouts et al. (2005) found that C. upsaliensis strain RM3195 was resistant to nalidixic acid (but 
not to ciprofl oxacin), but, unlike in our isolates, they were unable to detect any known quinolone 
resistance-associated mutations in the QRDR of gyrA, implying that also mechanisms other than 
those described in C. jejuni and C. coli play a part in quinolone resistance in this species.
All C. coli isolates highly resistant to erythromycin were found to have an A2122G mutation 
in the 23S rRNA encoding gene, which has been previously associated with erythromycin 
resistance in C. coli (29). However, we did not fi nd evidence that mutations in rplD or rplV 
would explain the decreased susceptibility to erythromycin (MIC 16-32 mg/l) in these C. coli 
isolates, as no previously described macrolide resistance-associated mutations were detected. 
Macrolide resistance-conferring mutations in the ribosomal protein L4 and L22 -encoding genes 
in Campylobacter spp. and other bacterial species have usually been located in the conserved 
region encoding amino acids 63-74 in L4 or leading to insertions or deletions of several amino 
acids in the C-terminal region of L22 (167, 171, 232-234). Even though we did detect several 
changes in both genes as compared with erythromycin-susceptible C. jejuni NCTC11168, the 
same genotypes were found in both susceptible and low-level resistant isolates. A more likely 
explanation for the observed low-level erythromycin resistance lies in the increased activity of 
the CmeABC effl  ux pump (168).
6.3  AssociaƟ ons of STR and ERY resistances in porcine C. coli 
and dynamics of STR resistance development aŌ er DANO 
and tylosin treatment
In a previous study, we observed an increase in the isolation rate of streptomycin-resistant C. coli 
following tylosin treatment of pigs at farm 1, where aminoglycosides had not been used in at least 
four years. In particular, occurrences of resistance to erythromycin, ciprofl oxacin, nalidixic acid 
and streptomycin were found to be signifi cantly higher among the isolates from treated pigs than 
from control animals (27). A common resistance mechanism for macrolides and quinolones is 
known to exist, namely the increased action of the CmeABC effl  ux pump, but nothing similar has 
been described for streptomycin. Th is led us to explore putative associations between resistance 
to streptomycin and erythromycin in C. coli. However, no obvious association between these 
resistance traits were detected, as the isolates did not become resistant to both aft er selection 
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with either agent in vitro and no changes in streptomycin MICs were detected aft er effl  ux 
pump inhibition. Further, at farm 3, even though resistance to streptomycin appeared already 
aft er weaning (25% of isolates were resistant), aft er danofl oxacin treatment 82% of the isolates 
from the treated group were streptomycin-resistant, suggesting that the use of danofl oxacin 
promoted their selection. However, tylosin treatment applied aft er danofl oxacin treatment was 
not observed to further increase the rate of streptomycin-resistant C. coli. On the contrary, aft er 
tylosin treatment, the frequency of streptomycin-resistant isolates in the treated group returned 
to a level close to that observed already aft er weaning and before danofl oxacin treatment. Our 
fi ndings indicate that the streptomycin-resistant isolates persisted at weaning units and were 
transferred to new batches of weaned pigs and selected in pigs treated with danofl oxacin. 
In light of the above-characterized streptomycin, erythromycin and fl uoroquinolone 
resistance mechanisms, no obvious connection between them can be seen, possibly indicating 
other epistatic mechanisms selecting for STR resistance alongside other resistance traits. For 
example, in a study conducted in E. coli in an antibiotic-free environment in vitro, specifi c 
combinations of point mutations in rpsL (including K43R) and gyrA alleles leading to a double-
resistant phenotype were found to exhibit positive epistasis (235).  Th e molecular targets and 
therefore resistance-conferring mutations of streptomycin, erythromycin and ciprofl oxacin 
occur in diff erent steps along the same pathway, e.g. protein synthesis, which could be one 
explanation of putative epistasis between these resistances.
It is noteworthy that both of these observations (statistically signifi cant increase in 
streptomycin resistance in C. coli aft er tylosin (27) or danofl oxacin treatment of pigs) were made 
in fi eld conditions, which is the likely environment of resistance development in the food chain. 
Th ese farm studies indicate that the dynamics of resistance development at farms are complex 
and can lead to multiresistance even when mechanistically unrelated antimicrobials are used.  
6.4  Occurrence of resistance in canine C. upsaliensis and 
C. jejuni 
Among the sampled dogs, all of the studied canine C. upsaliensis and C. jejuni isolates were, apart 
from streptomycin, highly susceptible to the antimicrobials investigated. Th e high streptomycin 
resistance rate detected in C. upsaliensis is concordant with fi ndings of previous studies (5, 
28). Also a low rate of quinolone resistance has been reported among C. upsaliensis from pets 
in several countries, including Belgium, Italy and Norway (28, 30, 236). No conclusions can, 
however, be drawn from this study on the prevalence of antimicrobial resistance in Campylobacter 
spp. among the dog population in Finland as only a small number of dogs belonging to a single 
breed was sampled.
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7  CONCLUSIONS
1. Mutations in codons 43 and 88 of the rpsL gene encoding the ribosomal protein S12 were 
found in all streptomycin resistant C. coli isolates and variants (but not their susceptible 
parents) indicating an association with streptomycin resistance. Only mutations of the non-
restrictive type were found in streptomycin-resistant isolates originating from pigs while 
in vitro-generated mutants exhibited both restrictive and non-restrictive mutations in rpsL 
and more diverse streptomycin MICs. Th is might be due to the slower growth rate of the 
isolates with restrictive rpsL mutations rendering them unable to survive competition in 
vivo as has been shown in other bacteria.
2. A novel resistance gene, ant-like gene A, was found to confer an intermediate level of 
streptomycin resistance in C. coli. Based on phylogenetic analysis, close homologues were 
not detected in any other bacterial species, except for ant-like gene B in C. jejuni, which, 
however, appeared not to be associated with streptomycin resistance.  Based on our fi ndings, 
it can be hypothesized that streptomycin resistance conferring ant-like gene A evolved from 
a common ancestral proto-resistance element in Campylobacter spp. 
3. Almost 80% of the studied canine C. upsaliensis isolates showed streptomycin MICs of >4 
mg/l, and mutations in rpsL codon 88 were found in all low-level streptomycin-resistant 
isolates, while rpsL rsmG double mutants exhibited a highly resistant phenotype. However, 
also streptomycin-susceptible C. upsaliensis isolates not harbouring any resistance-
associated mutations in either gene were detected, indicating streptomycin resistance is not 
intrinsic for C. upsaliensis.
4. Th e presence of streptomycin resistance genes and mutations in C. coli and C. upsaliensis 
populations derived from hosts that are known not to be exposed to streptomycin for long 
periods of time provides further evidence that merely ceasing antimicrobial usage will 
not completely eradicate resistant strains and suggests a low fi tness cost of streptomycin 
resistance in these Campylobacter species. Challenge with an antimicrobial belonging to a 
diff erent class appeared to select also streptomycin-resistant C. coli isolates. Th e observed 
increase of resistant isolates could be a consequence of co-selection mediated by some, yet 
uncharacterized, epistatic interactions.
5. All ciprofl oxacin-resistant C. coli isolates from pigs that had been administered danofl oxacin 
were found to harbour the commonly reported C257T mutation in gyrA, leading to T86I 
substitution and a high level of ciprofl oxacin resistance indicating that danofl oxacin does 
not induce novel mutations in the QRDR of gyrA in C. coli in vivo. However, the same C257T 
mutation in C. upsaliensis leads to T86M substitution and resistance to nalidixic acid, but 
only decreased sensitivity or low level resistance to ciprofl oxacin, implying that the most 
commonly described fl uoroquinolone resistance associated mutation in C. coli and C. jejuni 
is not suffi  cient to cause high level fl uoroquinolone resistance phenotype in C. upsaliensis.
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